

**Memorial Sloan Kettering Cancer Center (MSK)  
and Weill Cornell Medicine (WCM) Curriculum Vitae**

**Name:** Saad Zafar Usmani

**Signature:**



**Date of Preparation:** January 11, 2023

**A. PERSONAL DATA**

Office address:	530 East 74 <sup>th</sup> Street, New York, NY, 10021
Office telephone:	646-608-4132
Office fax:	929-321-7359
Home address:	1161 York Avenue, Apt#12E, New York, NY, 10065
Cell phone:	248-225-5642
Email address - Work:	<a href="mailto:usmanis@mskcc.org">usmanis@mskcc.org</a>
Email address - Personal:	saadzu@yahoo.com
Is your eligibility to work in the U.S. based on an employment visa?:	No
If yes, please provide Visa type (Example: J-1, H-1B, E-3, TN, etc.):	

**B. EDUCATION**

**Academic Degree(s)**

Degree (include field of study)	Institution name & Location	Dates attended	Year Awarded
MBBS	Allama Iqbal Medical College/University of the Punjab, Lahore, Pakistan	01/1997-05/2002	2002
MBA	Kenan-Flagler Business School, University of North Carolina, Chapel Hill, NC	12/2018-10/2020	2020

**Other Education Experiences**

Description	Institution Name & Location	Dates attended
HSSC	Crescent Model Higher Secondary School, Lahore, Pakistan	08/1994-08/1996

**C. POSTDOCTORAL TRAINING**

Title (include area of training)	Institution name & Location	Dates
Pathology Internship	Allama Iqbal Medical College & Jinnah Hospital, Pakistan	06/2002-01/2003
Radiology Internship	Punjab Medical College & Allied Hospital, Pakistan	03/2003-08/2003

<b>Title (include area of training)</b>	<b>Institution name &amp; Location</b>	<b>Dates</b>
Internal Medicine Residency	Sinai-Grace Hospital/Wayne State University, Detroit, MI	07/2004-06/2007
Hematology & Medical Oncology Fellowship	University of Connecticut Health Center, Farmington, CT	07/2007-06/2010

#### **D. PROFESSIONAL POSITIONS & EMPLOYMENT**

##### **Academic Appointments**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Assistant Professor of Medicine	University of Arkansas for Medical Sciences, Little Rock, AR	07/2010-06/2013
Adjunct Assistant Professor of Medicine	University of Arkansas for Medical Sciences, Little Rock, AR	07/2013-07/2014
Clinical Associate Professor of Medicine	UNC-Chapel Hill School of Medicine, Chapel Hill, NC	07/2013-12/2015
Clinical Professor of Medicine	UNC-Chapel Hill School of Medicine, Chapel Hill, NC	01/2016 – 10/2021
Member	Memorial Sloan Kettering Cancer Center New York, NY	11/2021 – present

##### **Hospital Appointments**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Attending Physician	University of Arkansas for Medical Sciences, Little Rock, AR	07/2010-06/2013
Attending Physician	Carolinas Medical Center, Charlotte, NC	07/2013-10/2021
Attending Physician	Hematology & Bone Marrow Transplant Levine Cancer Institute/Atrium Health, Charlotte, NC	07/2013-10/2021
Attending Physician	Memorial Hospital for Cancer and Allied Diseases New York, NY	11/2021-present

##### **Other Professional Positions & Employment**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Additional House Officer, Department of Radiology	Punjab Medical College & Allied Hospital Faisalabad, Pakistan	06/2002-01/2003
House Officer, Department of Pathology	Allama Iqbal Medical College & Jinnah Hospital Lahore, Pakistan	03/2003-08/2003
Clinical Research Assistant	Shaukat Khanum Memorial Cancer Hospital & Research Center Lahore, Pakistan	06/2003-06/2004

**E. LICENSURE, BOARD CERTIFICATION**

**Licensure:**

State	Number	Date of issue	Date of Expiration
New York	311514	2021	2023
New Jersey	25MA09379300	2013	2023
North Carolina	2013-01066	2013	2023
Connecticut	50733	2010	2023
South Carolina	87183	2021	2023

<b>DEA number:</b> (optional)	FU1919173
<b>NPI number:</b> (optional)	1962601526

**Board Certification**

Full Name of Board	Certificate # <i>(indicate if board eligible)</i>	Dates of Certification
ECFMG Permanent Certification	0-646-034-9	10/2003
ABIM Internal Medicine	284213	2007-2027
ABIM Hematology	284213	2010-2030
ABIM Medical Oncology	284213	2010-2030

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Diseases
Other Hospital Affiliations:	N/A
Other Institutional Affiliations:	Weill Cornell Medicine

**G. EMPLOYMENT STATUS**

<b>Name of Current Employer(s):</b>	Memorial Sloan Kettering Cancer Center
<b>Current Employment Status:</b>	- Full-time salaried by Cornell-affiliated hospital

**H. HONORS, AWARDS**

<b>Name of award</b>	<b>Organization</b>	<b>Date awarded</b>
1st Place Winner, Case Report Presentation	Sinai-Grace Hospital/Wayne State University, Detroit, MI	2005
Intern of the Year for Academic Excellence	Sinai-Grace Hospital/Wayne State University, Detroit, MI	2005
Finalist, Case Report Presentation Competition	National American College of Physicians (ACP) Meeting, Philadelphia, PA	2006

Finalist, Basic Science Research Competition	National American College of Physicians (ACP) Meeting, San Diego, CA	2007
Joseph E. Johnson American College of Physicians (ACP) Leadership Day Grant	American College of Physicians	2007
American Association of Cancer Research-American Society of Clinical Oncology (AACR-ASCO) Scholarship Award	Workshop Molecular Biology in Clinical Oncology, Aspen, CO	2008
Winner, University of Connecticut Health Center Multiple Myeloma Seed Grant Competition	University of Connecticut Health Center, Farmington, CT	2009
Member	International Myeloma Working Group	2010-present
Fellow	American College of Physicians	2011-present
Session Moderator, CLL (chronic lymphocytic leukemia) Oral Abstract Presentations	American Society of Hematology Annual Meeting	2012
Member, Scientific Committee on Lymphoma and Plasma Cell Disorders	American Society of Clinical Oncology	2012-2015
Session Chair, Myeloma Oral Abstract Presentations	American Society of Clinical Oncology Annual Meeting	2013
Track Leader, Scientific Committee on Lymphoma and Plasma Cell Disorders	American Society of Clinical Oncology	2014-2015
Member, American Society of Hematology (ASH) Scientific Committee on Plasma Cell Neoplasia	American Society of Hematology	2014-2020
Member	NCI Multiple Myeloma Steering Committee	2014-Present
Carolyn Wilson Courage Award	Lasco Cancer Foundation	2015
Session Chair, American Society of Clinical Oncology (ASCO) Myeloma Oral Abstract Presentations	American Society of Clinical Oncology	2015
Castle Connolly Top Doctor		2017-2021
Editor-in-Chief, American Society of Hematology (ASH) NewsDaily	American Society of Hematology	2017
Best Ambulatory Resident Award	Sinai-Grace Hospital/Wayne State University, Detroit, MI	2017
Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research Award	Leukemia & Lymphoma Society	2017-2022

Selected Late - Breaking Abstract, (Senior Author)	American Society of Clinical Oncology Annual Meeting	2018
Celgene Young Investigator Award for Hematology Research	Celgene	2018
Ad-hoc Member, American Society of Hematology (ASH) Program Committee	American Society of Hematology	2018-2020
Selected Late - Breaking Abstract, (First Author)	American Society of Clinical Oncology Annual Meeting	2019
Best Plenary Award	Japanese Society of Myeloma	2019
Vice Chair	American Society of Hematology (ASH) Scientific Committee on Plasma Cell Neoplasia	2019
Chair	American Society of Clinical Oncology (ASCO) Educational Committee on Plasma Cell Disorders	2019-2020
Multiple Myeloma Excellence in Research Award	International Congress on Controversies in Multiple Myeloma (COMy)	2020
Chair	American Society of Hematology (ASH) Scientific Committee on Plasma Cell Neoplasia	2020
Chair	American Society of Clinical Oncology (ASCO) Scientific Committee on Plasma Cell Disorders	2020-2021
Vice Chair	Southwest Cancer Chemotherapy Study Group (SWOG) Barlogie-Salmon Myeloma Committee	2020-present
Bart Barlogie Young Investigator Award for Clinical and Translational Research	International Myeloma Society	2021
Chair, Myeloma Committee	Alliance for Clinical Trials	2022-present

## I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS

<b>Organization</b>	<b>Date</b>
American College of Physicians (ACP)	2004-present
American Society of Clinical Oncology (ASCO)	2007-present
American Society of Hematology (ASH)	2007-present
American Association of Cancer Research (AACR)	2007-present
International Myeloma Working Group (IMWG)	2010-present
Southwest Cancer Chemotherapy Study Group (SWOG)	2010-2022
Association of Physicians of Pakistani Descent of North America	2010-present
Bone Marrow Transplant- Clinical Trials Network (BMT-CTN)	2010-present
European Hematology Association (EHA)	2010-present

National Cancer Institute (NCI) Multiple Myeloma Steering Committee	2014-present
Multiple Myeloma Research Consortium (MMRC)	2015-present
ALLIANCE for Clinical Trials	2021-present

**J. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

<b>MSK Activity</b>	<b>Percent Effort (%)</b>	<b>Does the activity involve MSK students/research trainees? (Yes/No)</b>	<b>Does the activity involve WCM students/research trainees? (Yes/No)</b>
Teaching	25	Y	Y
Clinical	40	Y	Y
Administrative	25	N	N
Research	10	Y	Y
<b>Total</b>	<b>100%</b>		

**K. EDUCATIONAL CONTRIBUTIONS**

**Teaching**

**Didactic teaching**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Department of General Surgery, UAMS Talkon "Overview of Multiple Myeloma Biology" Fellows and Faculty Division of Nephrology, UAMS	Trainees, surgical oncologists	2012
General Surgery Grand Rounds titled "Overview of Multiple Myeloma"	Trainees, hematologists, medical oncologists, surgical oncologists	2012
Winthrop P. Rockefeller Cancer Institute Noon Seminar, UAMS "State of the Art in Prognostication for Patients with Multiple Myeloma"	Trainees, hematologists, medical oncologists	2012
Winthrop P. Rockefeller Cancer Institute Noon Seminar, UAMS "Multiple Myeloma in 2012-Triumphs and Challenges"	Trainees, hematologists, medical oncologists	2012
International Myeloma Working Group Summit, Amsterdam, Netherlands "New Imaging in Myeloma-Role of MRI and PET"	Trainees, hematologists, medical oncologists	2012
ASH Annual Meeting Friday Satellite Symposium, Atlanta, GA "State of the Art in Prognostication for Patients with Multiple Myeloma"	Trainees, hematologists, medical oncologists	2012
Winthrop P. Rockefeller Cancer Institute Noon Seminar, UAMS "ASH 2012 – Highlights in Multiple Myeloma"	Trainees, hematologists, medical oncologists	2013

Graduate Course Titled “Pathobiology of Hematologic Malignancies: Myeloma” Graduate Program in Microbiology and Immunology, College of Medicine University of Arkansas for Medical Sciences, Little Rock, AR	Trainees, hematologists, medical oncologists	2013
FDA Multiple Myeloma Mini-Symposium, Silver Springs, MD “The Need for Surrogate Endpoints in MM Trials”	Trainees, hematologists, medical oncologists	2016

### Clinical teaching

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Teaching Medical Students, Internal Medicine Interns & Junior Residents Sinai-Grace Hospital/Wayne State University	Medical Students, Internal Medicine Interns & Junior Residents	2005-2007
Teaching Medical Students, Internal Medicine Interns & Residents Hematology-Oncology rotations at University of Connecticut Health Center & Affiliated Teaching Hospitals (Saint Francis Hospital and Hartford Hospital, Hartford, CT)	Teaching Medical Students, Internal Medicine Interns & Residents	2007-2010
Teaching Medical Students, Internal Medicine Interns, Residents and Hematology-Oncology Fellows at the University of Arkansas for Medical Sciences (UAMS), Little Rock, AR	Teaching Medical Students, Internal Medicine Interns & Residents, Hematology-Oncology Fellows	2010-2013
Teaching Medical Students, Internal Medicine Interns & Residents and Oncology Post-graduate Trainees, Allama Iqbal Medical College (AIMC), Lahore, Pakistan	Medical Students, Internal Medicine Interns & Residents and Oncology Post-graduate Trainees	2012
Teaching Medical Students, Internal Medicine Interns, Residents and Hematology-Oncology Fellows at the Carolinas Medical Center and Levine Cancer Institute, Charlotte, NC.	Teaching Medical Students, Internal Medicine Interns & Residents, Hematology-Oncology Fellows	2013-2021

### Administrative teaching

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
ACGME Key Clinical Faculty for Hematology-Oncology Fellowship, Levine Cancer Institute, Charlotte, NC	Hematology-Oncology Fellows	2014-2021

### Continuing education and professional education as teacher

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Chair, ASCO Direct Highlights	Trainees, hematologists, medical oncologists, pharmacists, nurses.	2017-2021

Chair, Charlotte Annual Hematologic Malignancies Congress	Trainees, hematologists, medical oncologists, pharmacists, nurses.	2018-2021
---	--	-----------

**Community education or patient outreach**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
MIRT Meet-Question & Answer Sessions with Patients & Caregivers (Conducted Bimonthly), UAMS	Patients & Caregivers	2011-2013
Myeloma Meet-Question & Answer Sessions with Patients & Caregivers (Conducted Quarterly), Levine Cancer institute, Charlotte, NC	Patients & Caregivers	2013-2021

**L. CLINICAL PRACTICE, INNOVATION, and LEADERSHIP**

**Clinical Practice**

<i>Duration</i>	<i>Name/Location of Practice</i>	<i>Type of Activity</i>	<i>Level of Activity</i>
8 years	Levine Cancer Institute, Charlotte, NC	Ambulatory Clinics	2 days/week
8 years	Carolinas Medical Center, Charlotte, NC	Inpatient BMT service	8-9 weeks/year
3 years	Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR	Ambulatory Clinics	4 days/week
3 years	University of Arkansas for Medical Sciences Medical Center, Little Rock, AR	Inpatient Myeloma & BMT service	12 weeks/year
2021-present	Memorial Sloan Kettering Cancer Center	Inpatient and Outpatient Service	1 day Op/week & 5 weeks IP service

**Clinical Innovations**

<i>Date Innovation Launched</i>	<i>Title/Location of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
---------------------------------	-------------------------------------	-------------	---



August 2013	Established the Plasma Cell Disorders Division at the Levine Cancer Institute	Chief	<ul style="list-style-type: none"> <li>Built the busiest bone marrow transplant for plasma cell disorders in the Carolinas, with over 7,000 clinic visits annually and performed over 600 transplants since 2014.</li> <li>Brought novel immunotherapies (CART cell therapies, bispecifics, trispecifics, etc.) in clinical investigations at LCI, first program in the Carolinas to offer this option to plasma cell disorders patients.</li> <li>Developed the clinical infrastructure to support multi-disciplinary care of plasma cell disorders patients, interfacing with other service lines within the healthcare organization.</li> <li>Hired 6 plasma cell disorders faculty since the inception of the program in 2013.</li> </ul>
November 2013	Started Clinical Trials unit focused on hematologic malignancies	Director	<ul style="list-style-type: none"> <li>Built and grew the infrastructure for clinical/translational research in blood cancers from the ground up.</li> <li>Built and maintaining a robust portfolio of first-in-human and early phase clinical trials in blood cancers, with over 200 clinical trials opened since 2013.</li> <li>Developed and help train a blood cancer and bone marrow transplant focused clinical trials unit, 26 FTE hires since 2013.</li> </ul>
September 2020	Started Day Hospital model to reduce ED visit and hospital admissions for the Cancer Center	Team leader	<ul style="list-style-type: none"> <li>Reduction in ED visits by 20%, reduction in hospital admissions by 8% over the next two quarters.</li> </ul>

### Clinical Leadership

Years	Leadership Role	Short Description of activity/program
-------	-----------------	---------------------------------------

8	Division Chief	<ul style="list-style-type: none"> <li>● <i>Founded the Plasma Cell Disorders Division. I presently lead a team of 7 clinicians, 2 mid-level providers and 2 lab researchers.</i></li> <li>● <i>Built an internationally recognized clinical and research programs in plasma cell disorders (multiple myeloma, amyloidosis, etc.) since the program's inception in 2013.</i></li> <li>● <i>Built the busiest bone marrow transplant for plasma cell disorders in the Carolinas, with over 7,000 clinic visits annually and performed over 600 transplants since 2014.</i></li> <li>● <i>Brought CART cell therapies in clinical investigations at LCI, first program in the Carolinas to offer this option to plasma cell disorders patients.</i></li> <li>● <i>Developed the clinical infrastructure to support multi-disciplinary care of plasma cell disorders patients, interfacing with other service lines within the healthcare organization.</i></li> </ul>
		<ul style="list-style-type: none"> <li>● <i>Hired 6 plasma cell disorders faculty since the inception of the program in 2013.</i></li> <li>● <i>Mentored 8 Hematology junior faculty to independent research careers.</i></li> <li>● <i>Recognized as one of the 22 Multiple Myeloma Research Foundation Centers of Excellence in the US since 2015.</i></li> <li>● <i>Published over 215 abstracts and over 165 peer-reviewed manuscripts in top tier journals including New England Journal of Medicine, Lancet, Lancet Oncology, Lancet Hematology, Journal of Clinical Oncology, Blood, Leukemia, etc.</i></li> <li>● <i>Secured both intramural and extra-mural funding of over \$11 million dollars to support research activities (National Cancer Institute, Internal Myeloma Foundation, Multiple Myeloma Research Foundation, Leukemia Lymphoma Society, Heinemann Foundation of Charlotte, Carolinas Myeloma Research Fund, Pharmaceutical partnerships).</i></li> <li>● <i>Leading clinical development programs of several small molecules and immunotherapies with pharmaceutical industry partnership.</i></li> </ul>

**M. RESEARCH**

I am an internationally recognized clinical and translational researcher in multiple myeloma and plasma cell disorders, with a 12+ year experience in various leadership roles. In my career so far, I have lead studies characterizing high risk multiple myeloma (MM) based on clinical and biologic features, as well as clinical and translational investigations focused on high-risk MM: I have identified the poor outcome of primary plasma cell leukemia (pPCL) in era of novel agents and also identified unique disease biology of pPCL by gene expression profiling [PMID: 22508408]. I have also reported on the incidence/patterns of extra-medullary disease (EMD) at

baseline and relapse in the largest cohort of myeloma patients with baseline PET-CT scans [PMID: 22689675], as well as clinical features of patients with central nervous system EMD [PMID: 24373936, 26955792]. This is an area of unmet need and I am developing focused clinical trials for this population. A major focus of my work has been on elucidating mechanisms of drug resistance in multiple myeloma to different novel drug classes such as proteasome inhibitors [PMID: 21628408, 24497533] and immunomodulatory drugs [PMID: 22855579, 25151956, 27496215]. I wrote and led the first national/inter-group clinical trial focused on newly diagnosed high risk MM (SWOG 1211 Study), comparing RVd with RVd-Elotuzumab [PMID: 26252787, PMID: 33357482]. This trial is a first step in the right direction, I am leading several phase I-III enrichment design trials for high-risk disease using CART and bispecific antibodies. I have evaluated the role of PET-CT prognostication [PMID: 23305732, 26690712], novel flow techniques for response assessment and immune - profiling as predictive biomarker for high-risk MM. I have also conducted investigator-initiated trials in a response-adaptive approach to overcome proteasome inhibitor and IMiD resistance [PMID: 25151956, 24326595, 27132469]. I have led several Phase I-III trials that using both intravenous and subcutaneous administration of the first active monoclonal antibody daratumumab (targeting CD38) for multiple myeloma.

The work has led to the approval of this drug as monotherapy as well as in combination for patients with newly diagnosed [PMID: 32804408, PMID: 31141632 ], early relapsed [PMID: 32682484, PMID: 33149130, PMID: 32457357, PMID: 31221782, PMID: 27705267 ] and late relapsed disease [PMID: 33145788, PMID: 32470437, PMID: 32354874, PMID: 32213342, PMID: 30395359]. I am leading and/or participating in the clinical development of next generation of drug classes and immunotherapies (CART and bispecific antibodies) for the therapy in high-risk MM [PMID: 26778538, 25594159, 25151956, 23456977, 23659971, 27216216].

### **Research Activities:**

<i>List IRB protocols (both active and inactive: IRB #, title, dates start-end or start- if ongoing, PI, and your role)</i>
N/A

### **Research Support:**

#### **Current Research Funding**

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	NCI-CTEP, BMS
<b>Project title:</b>	SWOG-1211: Phase I/II Trial Evaluating Optimal Induction Therapy for Newly Diagnosed High Risk Multiple Myeloma [NCT01668719]
<b>Annual direct costs:</b>	\$450,000
Duration of support:	2012-present
Name of Principal Investigator:	Serving as SWOG Study Chair
Your percent (%) effort:	5%
The major goals of this project are:	<i>Exploring Optimal therapy approach for high-risk MM in randomized phase II trial</i>
Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Multiple Myeloma Research Consortium Site Investment Grant
Project title:	Site Investment Grant
Annual direct costs:	\$ 175,500
Duration of support:	2021-present
Name of Principal Investigator:	<i>Saad Usmani</i>
Your percent (%) effort:	1%

The major goals of this project are:	<i>Oversee conduct of MMRC research projects</i>
Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Amgen
<b>Project title:</b>	Amgen 20160275: Phase III Study of Carfilzomib, Daratumumab and Dexamethasone for Patients with Relapsed and/or Refractory Multiple Myeloma. (CANDOR)
Annual direct costs:	Contract: \$1,270,820
Duration of support:	2017-present
Name of Principal Investigator:	<i>Study Chair and Steering Committee</i>
<b>Your percent (%) effort:</b>	2%
<b>The major goals of this project are:</b>	<i>Compare efficacy and safety of Carfilzomib, Daratumumab and Dexamethasone regimen in relapsed/refractory myeloma</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen
Project title:	MMY-3008: Phase III Study for Newly Diagnosed, Transplant Ineligible MM: Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs. Lenalidomide and Dexamethasone (Rd)
Annual direct costs:	Contract: \$1,253,185
Duration of support:	2015-present
Name of Principal Investigator:	<i>Steering Committee</i>
Your percent (%) effort:	2%
The major goals of this project are:	<i>Compare efficacy and safety of Daratumumab, Lenalidomide and Dexamethasone regimen in newly diagnosed myeloma</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Bart Barlogie Young Investigator Award
<b>Project title:</b>	Career Development Honorific Award
Annual direct costs:	\$25,000
Duration of support:	11/8/2021-11/7/2031
Name of Principal Investigator:	<i>Saad Usmani</i>
Your percent (%) effort:	No committed effort
The major goals of this project are:	Myeloma Research

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Fred's Team-Multiple Myeloma - Usmani
<b>Project title:</b>	Support smoldering and newly diagnosed MM translational projects
Annual direct costs:	\$128,003
Duration of support:	12/6/2021-12/5/2031
Name of Principal Investigator:	<i>Saad Usmani</i>
Your percent (%) effort:	No committed effort
The major goals of this project are:	Myeloma Research

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Multiple Myeloma Chief Fund
<b>Project title:</b>	Support smoldering and newly diagnosed MM clinical and translational projects
Annual direct costs:	\$0
Duration of support:	4/1/2022-12/30/2030
Name of Principal Investigator:	<i>Saad Usmani</i>
Your percent (%) effort:	No committed effort
The major goals of this project are:	Myeloma Research

### Past (Completed) Funding

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Leukemia Lymphoma Society Scholar in Clinical Research Award
Project title:	Optimizing Risk and Response Adaptive Strategies using Immunotherapy in Multiple Myeloma
Annual direct costs:	Award: \$550,000
Duration of support:	07/2017-06/2022
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	10%
The major goals of this project are:	<i>Conduct IITs focused on incorporating immune therapies in schema of myeloma therapy</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	National Cancer Institute Grant #U10CA180888 Sub-Investigator
Project title:	SWOG Network Group Operations Center of the NCTN
Annual direct costs:	Award: \$90,000
Duration of support:	05/15/2020 – 2/28/2022
Name of Principal Investigator:	<i>Charles Blanke</i>
Your percent (%) effort:	5%
The major goals of this project are:	<i>Protected time to serve as Vice-Chair for the SWOG Barlogie-Salmon Myeloma Committee</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants with Relapsed or Refractory Multiple Myeloma
Project title:	
Annual direct costs:	Contract: \$724,697
Duration of support:	2017-2021
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	2%
<b>The major goals of this project are:</b>	First-in-Human trials for BCMA directed bispecific antibody

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Sanofi TCD1479
---	----------------

Project title:	Phase I Trial of Isatuximab (SAR650984) With Pomalidomide-Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Annual direct costs:	Contract: \$415,075
Duration of support:	2015-2021
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of isatuximab, pomalidomide and dexamethasone combination in relapsed/refractory myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant) *	Janssen
Project title:	An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma ( MMY-1004)
Annual direct costs:	Contract: \$600,000
Duration of support:	2015-2021
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of subcutaneous formulation of daratumumab in relapsed/refractory myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant) *	BMS
Project title:	LCI-HEM-MYE-CRD-002 Phase II of Carfilzomib, Lenalidomide, Dexamethasone and Elotuzumab for Multiple Myeloma in First Relapse
Annual direct costs:	Award: \$940,929.79
Duration of support:	2017-2021
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of carfilzomib, lenalidomide, elotuzumab and dexamethasone combination for multiple myeloma in 1 <sup>st</sup> relapse

Award Source: (funding agency – federal, foundation, industry; type of grant) *	Amgen/Janssen/Celgene supported
Project title:	Phase II of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Newly Diagnosed Multiple Myeloma
Annual direct costs:	Award: \$2,325,000
Duration of support:	2018-2021
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of carfilzomib, lenalidomide, dexamethasone and daratumumab combination for newly diagnosed multiple myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant) *	Janssen supported
Project title:	LCI-HEM-MYE-PurD-001 Phase II of Daratumumab In-Vivo Purging for Transplant Eligible Newly Diagnosed Multiple Myeloma
Annual direct costs:	Award: \$700,000
Duration of support:	2018-2021
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of daratumumab prior to stem cell mobilization for newly diagnosed multiple myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant) *	(Merck supported)
Project title:	LCI-HEM-MYE-DPem-001 Phase II of Daratumumab-Pembrolizumab for Relapsed and/or Refractory Diagnosed Multiple Myeloma
Annual direct costs:	Award: \$900,000
Duration of support:	2018-2021
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of daratumumab and pembrolizumab combination for relapsed/refractory multiple myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant) *	International Myeloma Foundation/Black Swan Initiative Grant
Project title:	Incorporating Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma Therapy
Annual direct costs:	Award: \$ 178,000
Duration of support:	2015-2021

Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	2%
The major goals of this project are:	<i>Testing and validation of MRD testing by NGF in clinical practice</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Heineman Foundation of Charlotte
Project title:	Exploratory Study of Peripheral Blood Immune Profiling as a Predictive Biomarker for Survival Outcomes in Multiple Myeloma Patients Receiving Novel Immunotherapy Based Treatment
Annual direct costs:	Award: \$ 65,000
Duration of support:	2016-2021
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	5%
The major goals of this project are:	<i>Exploratory study of correlating peripheral blood immune profiling with MRD based response to therapy</i>

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	National Cancer Institute R01 CA201634-01 (4th Percentile)
Project title:	PET Scan for Prognostication in Newly Diagnosed High Risk Multiple Myeloma
Annual direct costs:	Award: \$940,339
Duration of support:	12/15/2015 – 12/31/2017
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	5%
The major goals of this project are:	Evaluate PET-CT as a prognostic tool on the SWOG 1211 trial

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Merck Keynote 183
Project title:	Phase III Study of Pomalidomide and Low Dose Dexamethasone with or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma
Annual direct costs:	Contract: \$217,870
Duration of support:	2016-2017
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of pomalidomide, dexamethasone and pembrolizumab combination for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Celgene
Project title:	A Phase 1b multicenter, open-label study to determine the Recommended Dose and Regimen of durvalumab (MEDI4736) (DUR), an anti-programmed cell death ligand 1 (PD-L1) antibody, either as monotherapy or in combination with pomalidomide (POM) with or without low dose- dexamethasone (dex) in subjects with Relapsed and Refractory Multiple Myeloma (RRMM).



Annual direct costs:	Contract: \$731,698
Duration of support:	2016-2017
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of pomalidomide, dexamethasone and durvalumab combination for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Merck Keynote 185
Project title:	Phase III Study of Lenalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Annual direct costs:	Contract: \$1,280,270
Duration of support:	2016-2017
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of lenalidomide, dexamethasone and pembrolizumab combination for newly diagnosed multiple myeloma

MMRC

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	
Project title:	MMRC-071 Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma
Annual direct costs:	Contract: \$217,870
Duration of support:	2015-2017
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of elotuzumab, lenalidomide, dexamethasone combination for smoldering multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Prothena
Project title:	Prothena VITAL Study: Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients with AL Amyloidosis
Annual direct costs:	Contract: \$223,610
Duration of support:	2015-2017
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of NEOD001 for relapsed/refractory AL Amyloidosis

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen MMY-3010
Project title:	An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy; Early Access Protocol (EAP)
Annual direct costs:	Contract: \$376,379.70

Duration of support:	2015-2016
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of daratumumab for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Onyx-Amgen OPZ007
Project title:	Phase Ib/III Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects [NCT01999335]
Annual direct costs:	Contract: \$257,270
Duration of support:	2014-2016
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of oprozomib, pomalidomide, dexamethasone combination for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	MMRC-044
Project title:	Phase II Trial of RVD-Elotuzumab for Newly Diagnosed Transplant Eligible Multiple Myeloma
<b>Annual direct costs:</b>	
Duration of support:	2015-2016
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of elotuzumab, lenalidomide, bortezomib and dexamethasone combination for newly diagnosed multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	MMRC CoMMpass
Project title:	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile [NCT01454297]
Annual direct costs:	Contract: \$241,350
Duration of support:	2014-2015
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Prospective collection of specimen for immune and genomic analyses to explore prognostic and predictive models in MM

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Array BioPharma ARRY-215
Project title:	A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) [NCT02092922]
Annual direct costs:	Contract: \$729,953
Duration of support:	2014-2015

<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of filanesib for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Array BioPharma ARRY-216
<b>Project title:</b>	A Multicenter, Randomized, Open-label, Phase II Study of Carfilzomib with or Without ARRY-520 and in Patients with Advanced Multiple Myeloma [NCT01989325]
<b>Annual direct costs:</b>	Contract: \$432,286
<b>Duration of support:</b>	2013-2015
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of fianesib and carfilzomib combination for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Pharmacyclics PCYC 1119-CA
<b>Project title:</b>	Phase I/IIb of Carfilzomib + Ibrutinib for MM with > 2 Prior Lines of Therapy [NCT01962792].
<b>Annual direct costs:</b>	Contract: \$486,498
<b>Duration of support:</b>	2013-2014
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of carfilzomib and ibrutinib combination for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen MMY-3003
<b>Project title:</b>	Phase III Study for MM > 1 Prior Line(s) of Therapy: Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs. Lenalidomide and Dexamethasone (Rd) [NCT01615029]
<b>Annual direct costs:</b>	Contract: \$788,660
<b>Duration of support:</b>	2014-2015
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of daratumumab, lenalidomide, dexamethasone combination for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen MMY-2002
<b>Project title:</b>	Open-label, Multicenter, Phase II Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD [NCT01985126]

Annual direct costs:	Contract: \$600,542
Duration of support:	2013-2014
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of intravenous daratumumab for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Array BioPharma Research Grant
Project title:	Exploratory Pre-clinical Study of Melphalan and Filanesib in Multiple Myeloma
Annual direct costs:	Contract: \$20,000
Duration of support:	2014-2015
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of pomalidomide, dexamethasone and pembrolizumab combination for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Total Therapy 5A
Project title:	A Phase II Trial for High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by applying Non-Host-Exhausting and Timely Dose-Reduced MEL- 80+VRD-PACE Tandem Transplants with Interspersed MEL-20-VTD-PACE and VRD Maintenance [NCT00869232]
Annual direct costs:	Contract: \$ 450,000
Duration of support:	2011-2013
Name of Principal Investigator:	
Your percent (%) effort:	
The major goals of this project are:	

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Senesco
Project title:	Senesco Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma [NCT01435720]
Annual direct costs:	Contract: \$ 719,784
Duration of support:	2011-2013
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	1%
The major goals of this project are:	Assess safety and efficacy of SNS01-T for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Millenium/Takeda
<b>Project title:</b>	Phase III Randomized Double Blinded Multi-Center Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma. [NCT01564537].
<b>Annual direct costs:</b>	Contract: \$416,906
<b>Duration of support:</b>	2012-2013
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of Ixazomib, lenalidomide, dexamethasone combination for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Celgene
<b>Project title:</b>	Phase II Trial of Pomalidomide in High-Risk Relapsed and/or Refractory Multiple Myeloma [NCT01177735]
<b>Annual direct costs:</b>	Contract: \$650,070
<b>Duration of support:</b>	2012-2013
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of pomalidomide for high-risk relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Binding Site
<b>Project title:</b>	Evaluation of Hevlyte Assay as a Marker of Response and Disease Progression in Newly Diagnosed MM
<b>Annual direct costs:</b>	Contract: \$15,000
<b>Duration of support:</b>	2012-2013
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess prognostic role of the Hevlyte assay in newly diagnosed multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Onyx Pharmaceuticals
<b>Project title:</b>	Onyx Research Grant for Clinical Investigations Incorporating Carfilzomib for Newly Diagnosed and Previously Treated High Risk Multiple Myeloma
<b>Annual direct costs:</b>	Contract: \$ 1,000,000
<b>Duration of support:</b>	2011-2013
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of carfilzomib for newly diagnosed and

	previously treated high-risk multiple myeloma
<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Janssen
<b>Project title:</b>	A Study of the Safety and Efficacy of CNTO 328 in Combination with Best Supportive Care Compared to Best Supportive Care in Patients with Multicentric Castleman's Disease [NCT01024036]
<b>Annual direct costs:</b>	Contract: \$330,660
<b>Duration of support:</b>	2011-2012
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of Siltuximab for multi-centric Castleman's Disease

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	University of Connecticut Health Center Multiple Myeloma Seed Grant
<b>Project title:</b>	"Exploratory Study of gp96 inhibition in multiple myeloma"
<b>Annual direct costs:</b>	Contract: \$20,000
<b>Duration of support:</b>	2009-2010
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Preclinical models of gp96 inhibition in multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Carole & Ray Neag Comprehensive Cancer Center/HERA Foundation Seed Grant
<b>Project title:</b>	"Pilot study on incidence of transient bacteremia and blood stream infections due to dental procedures in cancer patients with central venous catheters".
<b>Annual direct costs:</b>	Contract: \$15,000
<b>Duration of support:</b>	2009-2010
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	1%
<b>The major goals of this project are:</b>	Assess safety and efficacy of pomalidomide, dexamethasone and pembrolizumab combination for relapsed/refractory multiple myeloma

<b>Award Source:</b> <i>(funding agency – federal, foundation, industry; type of grant) *</i>	CO1 U10CA180888 NCTN OHSU
<b>Project title:</b>	<b>SWOG Myeloma Committee Vice Chair</b>
<b>Annual direct costs:</b>	\$43117
<b>Duration of support:</b>	11/1/2021-1/15/2022
<b>Name of Principal Investigator:</b>	Saad Usmani
<b>Your percent (%) effort:</b>	(Terminated 1/15/22)
<b>The major goals of this project are:</b>	Oversee MM clinical trial development within SWOG Cooperative Group

Pending Funding: N/A

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	Leukemia Lymphoma Society (LLS)
<b>Project title:</b>	Career Development Award
Annual direct costs:	\$69,842
Duration of support:	11/1/2021-6/30/2022
Name of Principal Investigator:	Saad Usmani
<b>Your percent (%) effort:</b>	25%
<b>The major goals of this project are:</b>	Provide salary support for MM research projects

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	MED22-024 (Gilead Sciences)
Project title:	Phase 2 Multi-Arm Study of Magrolimab Combination in Patients with Relapsed/Refractory Multiple Myeloma
Annual direct costs:	\$0
Duration of support:	5/23/2022-5/22/2031
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	Potential trial to be opened at MSK
<b>The major goals of this project are:</b>	Assess safety and efficacy of magrolimab combinations for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	MED22-065 (Janssen Pharmaceutical)
Project title:	Phase 1B Study of Bispecific T cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of P with Relapsed/Refractory Multiple Myeloma
Annual direct costs:	\$0
Duration of support:	4/14/2022-4/13/2032
Name of Principal Investigator:	Saad Usmani
Your percent (%) effort:	Potential trial to be opened at MSK
<b>The major goals of this project are:</b>	Assess safety and efficacy of teclistimab/cetrlimab and Talquetamab/cetrlimab combinations for relapsed/refractory multiple myeloma

Award Source: <i>(funding agency – federal, foundation, industry; type of grant) *</i>	MED22-082 (Celgene Corporation)
Project title:	An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed/Refractory Multiple Myeloma
Annual direct costs:	\$0
Duration of support:	5/3/2022-5/2/2032
Name of Principal Investigator:	Saad Usmani



Your percent (%) effort:	Potential trial to be opened at MSK
The major goals of this project are:	Assess safety and efficacy of CC-92480 combinations for relapsed/refractory multiple myeloma

### Patents & Inventions

Inventors	Title of Invention	Patent Number
N/A		

### N. MENTORING

#### Current Mentees

Name	Carlyn Tan, MD
Site/Position	Junior Faculty, Myeloma Service, MSKCC
Mentoring Period	2021-Present
Project/Accomplishments**,	Career Development foundation grant recipient
Current Position	Assistant Member L1
Type of Supervision (Research, clinical, teaching, leadership)	Lead author on 2 IITs, clinical research mentee focused on MGUS, SMM and newly diagnosed MM.

Name	Urvi Shah, MD
Site/Position	Junior Faculty, Myeloma Service, MSKCC
Mentoring Period	2021-Present
Project/Accomplishments**,	Career Development foundation grant recipient
Current Position	Assistant Member
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee focused on modifiable risk factors in MM and plasma cell disorders

Name	Kylee MacLachlan, MD PhD
Site/Position	Junior Faculty, Myeloma Service, MSKCC
Mentoring Period	2022-Present
Project/Accomplishments**,	Career Development foundation grant recipient
Current Position	Assistant Member L1
Type of Supervision (Research, clinical, teaching, leadership)	Lead author on 1 IIT, clinical/translational research mentee focused on MM genomics

Name	Neha Korde, MD
Site/Position	Junior Faculty, Myeloma Service, MSKCC
Mentoring Period	2021-Present
Project/Accomplishments**,	Developing two IITs, as well as several QI operational projects to improve access to care in the regional sites
Current Position	Assistant Member
Type of Supervision (Research, clinical, teaching, leadership)	Lead author on 2 IITs, clinical research mentee focused on MGUS, SMM and newly diagnosed MM.

Name	Malin Hultcrantz, MD
Site/Position	Junior Faculty, Myeloma Service, MSKCC
Mentoring Period	2021-Present
Project/Accomplishments**	ASCO 2022 presentations as senior author



<i>Current Position</i>	<i>Assistant Member</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Lead author on 3 IITs, clinical/translational research mentee focused on epidemiology and novel therapies in relapsed MM.</i>
<i>Name</i>	<i>Sham Mailankody, MD</i>
<i>Site/Position</i>	<i>Junior Faculty, Myeloma Service, MSKCC</i>
<i>Mentoring Period</i>	<i>2021-Present</i>
<i>Project/Accomplishments**,</i>	<i>Developing concepts on sequencing CART and bispecific antibodies, investigating mechanism of resistance to T cell redirection strategies.</i>
<i>Current Position</i>	<i>Associate Member</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Lead author on 4 IITs, clinical/translational research mentee focused on cellular therapies in relapsed MM.</i>

**Past Mentees:**

<i>Name</i>	<i>Barry Paul, MD</i>
<i>Site/Position</i>	<i>Junior Faculty, Plasma Cell Disorders Division, Levine Cancer Institute, Charlotte, NC</i>
<i>Mentoring Period</i>	<i>2019-2021</i>
<i>Project/Accomplishments**,</i>	<i>Lead author on 1 IIT, 3 first author papers.</i>
<i>Current Position</i>	<i>Assistant Professor</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Brittany Ragon, MD</i>
<i>Site/Position</i>	<i>Junior Faculty, Leukemia Division, Levine Cancer Institute, Charlotte, NC</i>
<i>Mentoring Period</i>	<i>2017-2021</i>
<i>Project/Accomplishments**,</i>	<i>Lead author CIBMTR project</i>
<i>Current Position</i>	<i>Assistant Professor</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Shebli Atrash, MD</i>
<i>Site/Position</i>	<i>Junior Faculty, Plasma Cell Disorders Division, Levine Cancer Institute, Charlotte, NC.</i>
<i>Mentoring Period</i>	<i>2017-2021</i>
<i>Project/Accomplishments**,</i>	<i>Lead author on review and research manuscripts, co-investigator on 2 investigator- initiated protocol</i>
<i>Current Position</i>	<i>Assistant Professor</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

--	--

Name	Bei Hu, MD.
Site/Position	Junior Faculty, Lymphoma Division, Levine Cancer Institute, Charlotte, NC.
Mentoring Period	2015-2021
Project/Accomplishments**,	Projects focused on healthcare disparities
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Manisha Bhutani, MD
Site/Position	Junior Faculty, Plasma Cell Disorders Division, Levine Cancer Institute, Charlotte, NC
Mentoring Period	2014-2021
Project/Accomplishments**,	Recipient, ASCO Young Investigator Award; multiple 1 <sup>st</sup> author papers on IP/MRD related manuscripts
Current Position	Associate Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical and translational research mentee

Name	Reed Friend, MD
Site/Position	Junior Faculty, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC
Mentoring Period	2016-2019
Project/Accomplishments**,	Lead author on review and research manuscripts, co-investigator on 1 investigator-initiated protocol.
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Megan Jagosky, MD
Site/Position	Former Fellow, Junior Faculty at Levine Cancer Institute, Charlotte, NC
Mentoring Period	2015-2020
Project/Accomplishments**,	Lead author on ASH poster presentations and 3 manuscripts
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	M. Junaid Hussain, MD
Site/Position	Former Fellow, now Assistant Professor at Rush University Medical Center Hematology/BMT Program, Chicago
Mentoring Period	2015-2018
Project/Accomplishments**,	Lead author on 3 manuscripts and 1 investigator-initiated protocol.
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Ryan Jacobs, MD
Site/Position	Junior Faculty, Lymphoma Division, Levine Cancer Institute, Charlotte, NC.
Mentoring Period	2015- 2019
Project/Accomplishments**,	Developed CLL clinical research program
Current Position	Associate Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee.

Name	Christianne Bourlon, MD
Site/Position	Instituto Nacional de Ciencias Medicas Nutricion Salvador Zubiran, Mexico City
Mentoring Period	2015
Project/Accomplishments**,	ASCO International Development and Education Award
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Preeya Patel
Site/Position	MPH Graduate Student, UNC School of Public Health Class 2016
Mentoring Period	2014-2015
Project/Accomplishments**,	Lead author on AACR 2015 poster presentation.
Current Position	Industry
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Amanda Tullos
Site/Position	Medical Student Year 1, UAMS School of Medicine
Mentoring Period	2012-2013
Project/Accomplishments**,	Serving as Research Preceptor for this student, co-authored 1 ASCO abstract
Current Position	Assistant Professor
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Mohammad Atiq
Site/Position	Medical Student Year 4, UAMS School of Medicine
Mentoring Period	2012-2013
Project/Accomplishments**,	Serving as Research Preceptor for this student, co-authored 1 case report
Current Position	Fellow, NCI
Type of Supervision (Research, clinical, teaching, leadership)	Clinical research mentee

Name	Mariam Boota, MD
Site/Position	(Post-Doctoral Student)
Mentoring Period	2012-2013

<i>Project/Accomplishments**,</i>	<i>Lead author/co-author on one book chapter and two manuscripts</i>
<i>Current Position</i>	<i>Industry</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Al-Ola Abdallah, MD.</i>
<i>Site/Position</i>	<i>Hospitalists/UAMS Little Rock AR</i>
<i>Mentoring Period</i>	<i>2012-2013</i>
<i>Project/Accomplishments**,</i>	<i>Lead author/co-author on two ASH abstracts and two manuscripts</i>
<i>Current Position</i>	<i>Assistant Professor, University of Kansas Cancer Center</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Jameel Muzaffar, MD</i>
<i>Site/Position</i>	<i>3rd Year Hematology-Oncology Fellow, UAMS, Little Rock, AR</i>
<i>Mentoring Period</i>	<i>2011-2013</i>
<i>Project/Accomplishments**,</i>	<i>Lead author/co-author on two ASH abstracts, three manuscripts</i>
<i>Current Position</i>	<i>Private practice</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Nabeel Chauhan, MD (Post-Doctoral Student)</i>
<i>Site/Position</i>	<i>3rd Year Neurology Residency, UAMS, Little Rock, AR</i>
<i>Mentoring Period</i>	<i>2011-2012</i>
<i>Project/Accomplishments**,</i>	<i>Lead author/co-author on three manuscripts</i>
<i>Current Position</i>	<i>Private practice</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Ruby Sharma</i>
<i>Site/Position</i>	<i>4th Year Hematology-Oncology Fellow, Hofstra University-Long Island Jewish Cancer Center, New York, NY</i>
<i>Mentoring Period</i>	<i>2007-2010</i>
<i>Project/Accomplishments**,</i>	<i>Lead author/co-author two abstracts and one case report.</i>
<i>Current Position</i>	<i>Private practice</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

<i>Name</i>	<i>Rashid Khan, MD</i>
<i>Site/Position</i>	<i>Internal Medicine Residency, University of Connecticut Health Center, CT</i>
<i>Mentoring Period</i>	<i>2007-2010</i>
<i>Project/Accomplishments**,</i>	<i>Lead author/co-author two abstract and one review paper.</i>
<i>Current Position</i>	<i>Private practice</i>
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	<i>Clinical research mentee</i>

**Institutional Training Grants and Mentored Trainee Grants**

Award Source: (funding agency, type of grant)	N/A
Project title:	
Duration of support:	
Mentee (if applicable):	

**Other mentoring activities**

<i>Activity</i>	<i>Dates</i>
N/A	

**O. INSTITUTIONAL LEADERSHIP ACTIVITIES**

<i>Role(s)/Position</i>	<i>Institution/Location</i>	<i>Dates</i>
Director of Developmental Therapeutics	Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR	07/2011-07/2013
Chief, Division of Plasma Cell Disorders	Levine Cancer Institute/Atrium Health, Charlotte, NC	07/2013-10/2021
Director of Clinical Research for Hematologic Malignancies	Levine Cancer Institute/Atrium Health, Charlotte, NC	07/2013-10/2021
Chief of Myeloma Service	MSK	11/2021 onwards

**P. INSTITUTIONAL ADMINISTRATIVE ACTIVITIES**

<i>Name of Committee</i>	<i>Role</i>	<i>Dates</i>
Educational Curriculum Committee Sinai-Grace Hospital/Wayne State University, Detroit, MI	Member	2004-2007
Residency Operations Committee Sinai-Grace Hospital/Wayne State University, Detroit, MI	Member	2004-2007
Wayne State University Resident's Council	Representative	2006-2007
Curriculum Committee, Hematology Oncology Fellowship University of Connecticut Health Center, CT	Member	2008-2010
Cancer Committee, University of Connecticut Health Center	Member	2008-2010
MIRT Finance/Operations Committee, UAMS, Little Rock, AR	Member	2010-2013
Myeloma Translational Research Group, UAMS, Little Rock, AR	Member	2010-2013
Pathology Chair Search Committee, UAMS, Little Rock, AR	Member	2010-2011

Medical Student Interview Committee UAMS School of Medicine Class of 2012	Member	2011
Clinic Efficiency Committee Levine Cancer Institute, Charlotte, NC	Member	2013-2015
Bone Marrow Transplant Operations Committee Levine Cancer Institute, Charlotte, NC	Member	2013-2021
Bone Marrow Transplant Operations Committee Levine Cancer Institute, Charlotte, NC	Member	2013-2021
Phase I Trials Committee Levine Cancer Institute, Charlotte, NC	Member	2013-2021
PI Oversight Committee Levine Cancer Institute, Charlotte, NC	Member	2014-2021
Hematology-Oncology Fellowship Program Levine Cancer Institute, Charlotte, NC	Key Clinical Faculty	2015-2021
Cancer Committee Levine Cancer Institute, Charlotte, NC	Member	2016-2021
Bylaws Committee Carolinas Medical Center (Main), Charlotte, NC	Member	2016-2021
Hematology Service Chief Search Committee, Division of Hematologic Malignancies (DHM), Memorial Sloan Kettering Cancer Center (MSKCC)	Member	2021-2022
Cellular Therapy Service Chief Search Committee, Division of Hematologic Malignancies (DHM), Memorial Sloan Kettering Cancer Center (MSKCC)	Member	2021-2022
Department of Medicine Executive Council	Member	2021-present
Memorial Sloan Kettering Cancer Center (MSK) National Cancer Institute (NCI) Network Program Committee	Member	2022-present
Division of Hematologic Malignancies (DHM) Clinical Research Task Force	Member	2022-present
Research Council, Memorial Sloan Kettering Cancer Center (MSKCC)	Member	2022-present

**Q. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

**Leadership in Extramural Organizations**

<i>Organization</i>	<i>Role</i>	<i>Dates</i>
<i>American Society of Hematology</i>	<i>Member, Abstract Review Committee</i>	<i>2012, 2017, 2018, 2021</i>
<i>American Society of Hematology</i>	<i>Chair (2020), Vice Chair (2019), Member (2014-2018) Scientific Committee on Plasma</i>	<i>2014-2020</i>

	<i>Cell Neoplasia</i>	
<i>American Society of Hematology</i>	<i>Ad-hoc Member, Annual Meeting Program Committee</i>	<i>2018-2020</i>
<i>American Society of Clinical Oncology</i>	<i>Chair, Annual Meeting Educational Committee on Plasma Cell Disorders</i>	<i>2019-2020</i>
<i>International Myeloma Society</i>	<i>Chair, Social Media Committee</i>	<i>2020-onwards</i>
<i>American Society of Clinical Oncology</i>	<i>Chair, Annual Meeting Scientific Committee on Plasma Cell Disorders</i>	<i>2020-2021</i>

### Service on Boards and/or Committees

#### Regional

N/A

#### National

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
National ACP Medical Student Abstract Competition	Member, Editorial Review Board	American College of Physicians	2007-2015
National ACP Associate Member Abstract Competition	Member, Editorial Review Board	American College of Physicians	2008-2015
Barlogie-Salmon Myeloma Committee	Member (2010-2019), Vice-Chair (2020 onwards)	SWOG	2010-2022
Imaging Committee	Member	SWOG	2012-2022
Myeloma Steering Committee	Member	National Cancer Institute	2014-onwards
Social Media Committee	Member	SWOG	2019-2022
Myeloma Committee	Chair	ALLIANCE	2022-onwards

#### International

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
<i>International Myeloma Working Group</i>	<i>Member</i>	<i>International Myeloma Foundation</i>	<i>2010-onwards</i>
<i>Abstract Review Committee</i>	<i>Member</i>	<i>American Society of Hematology</i>	<i>2012, 2017, 2018, 2021</i>
<i>Scientific Committee on Plasma Cell Neoplasia</i>	<i>Chair (2020), Vice Chair (2019), Member (2014-2018)</i>	<i>American Society of Hematology</i>	<i>2014-2020</i>
<i>Annual Meeting</i>	<i>Ad-hoc Member</i>	<i>American Society of Hematology</i>	<i>2018-2020</i>

<i>Program Committee</i>			
<i>Annual Meeting Educational Committee on Plasma Cell Disorders</i>	<i>Chair</i>	<i>American Society of Clinical Oncology</i>	<i>2019-2020</i>
<i>Annual Meeting Scientific Committee on Plasma Cell Disorders</i>	<i>Chair</i>	<i>American Society of Clinical Oncology</i>	<i>2020-2021</i>
<i>Social Media Committee</i>	<i>Chair</i>	<i>International Myeloma Society</i>	<i>2020-onwards</i>

### **Grant Reviewing/Study Sections**

<i>Role(s)</i>	<i>Organization Name</i>	<i>Dates</i>
Reviewer	National Cancer Institute- CTEP MYSC	2011-present
Reviewer	International Myeloma Foundation Brian D. Novis Research Award	2012-2015
Reviewer	Austrian Science Foundation	2013-2014
Reviewer	Health Research Board, Dublin, Ireland	2013-2014
Reviewer	National Institutes H Cancer Biomarkers (CBSS) Study Section Translational Clinical IRG (OTC)	2014-2015
Reviewer	American Association for the Advancement of Science (AAAS)	2014-2015
Reviewer	National Cancer Institute PO1 Review Panel , Special Emphasis Panel/Scientific Review Group	2018
Reviewer	National Cancer Institute SPORE Review Panel, Special Emphasis Panel/Scientific Review Group	2020
Reviewer	National Cancer Institute SPORE Review Panel, Special Emphasis Panel/Scientific Review Group	2021
Reviewer	National Cancer Institute PO1 Review Panel, Special Emphasis Panel/Scientific Review Group	2022
Reviewer	National Cancer Institute- CTEP BMT-CTN Progress Review	2022

### **Editorial Activities**

#### **Journal Reviewing/ad hoc reviewing**

<i>Journal / Organization Name</i>	<i>Dates</i>
Journal of Clinical Oncology	2010-present
Journal of Hematologic Malignancies	2011-present
Experimental Hematology & Oncology	2011-present
Leukemia	2011-present
Bone Marrow Transplant	2011-present
Biology of Bone Marrow Transplantation	2011-present
Modern Chemotherapy	2012-present
Haematologica	2012-present
American Journal of Hematology	2012-present
Blood Cancer Journal	2012-present
Annals of Hematology	2013-present
Leukemia Research	2013-present
Journal of Onco-Pathology	2013-present
Blood	2013-present
British Journal of Hematology	2013-present
Hem-Onc Today	2014-present



Clinical Oncology News	2015-2017
------------------------	-----------

**Editor/Co-Editor**

<i>Books / Textbooks / Journals / Organization Name</i>	<i>Dates</i>
American Society of Hematology News Daily	2017

**Editorial Board Membership**

<i>Board / Organization Name</i>	<i>Dates</i>
National American College of Physicians Medical Student Abstract Competition	2007-2015
National American College of Physicians (ACP) Associate Member Abstract Competition	2008-2015

**R. INVITATIONS TO SPEAK/PRESENT**

**Regional**

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
N/A		

**National**

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
"Updates on Multiple Myeloma Therapy"	Connecticut Pharmacist Association Meeting, Farmington, CT.	2009
"gp96 Inhibition in Myeloma Therapy"	Medical College of Georgia Cancer Center, Augusta, GA.	2009
"HSP90 Inhibition in Myeloma Therapy"	Winship Cancer Institute, Emory University, Atlanta, GA.	2009
"Designing a High-Risk Myeloma Trial-Lessons from the UAMS Experience"	SWOG Spring 2011 Meeting, San Francisco, CA	April 2011
"Advances in Myeloma Genomics"	University of Illinois Chicago Division of Hematology-Oncology Grand Rounds, Chicago, IL	July 2011
"Impediments to Curing Myeloma"	University of Cincinnati Division of Hematology-Oncology Grand Rounds, Cincinnati, OH.	September 2011
"SWOG High-Risk Myeloma Clinical Trial Proposal"	SWOG Fall 2011 Meeting, San Antonio, TX	October 2011
"Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide versus Thalidomide in Maintenance Phases"	American Society of Hematology (ASH) 2011 Annual Meeting, San Diego, CA.	December 2011
"Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated on Total Therapies 2 & 3-Influence of Cumulative Dosing of Maintenance Drugs".	American Society of Hematology (ASH) 2012 Annual Meeting, Atlanta, GA	December 2012

“State of the Art for Determining Prognosis for Patients with Multiple Myeloma: 2012”	American Society of Hematology (ASH) 2012 Annual Meeting Friday Satellite Symposium, Atlanta, GA	December 2012
Highlights of Myeloma Oral Abstracts	American Society of Clinical Oncology 2013 Annual Meeting, Chicago, IL	June 2013
Best of ASCO 2013: Lymphoma & Myeloma Abstracts	Chicago, IL	August 2013
Best of ASCO 2013: Lymphoma & Myeloma Abstracts	Boston, MA	August 2013
Highlights of Myeloma Oral Abstracts,	American Society of Clinical Oncology 2014 Annual Meeting, Chicago, IL	June 2014
“Are We Ready for Biomarker Driven Therapy in Multiple Myeloma”,	American Society of Clinical Oncology 2015 Annual Meeting, Chicago, IL	June 2015
“Optimal Management of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients”	American Society of Clinical Oncology 2015 Annual Meeting, Chicago, IL	June 2015
“Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma”	American Society of Hematology (ASH) 2015 Annual Meeting, Orlando, FL	December 2015
“Updates on Options for Relapsed/Refractory Disease”	Multiple Myeloma Research Foundation American Society of Hematology (ASH) Friday Satellite Symposium, ASH 2015 Annual Meeting, Orlando, FL	December 2015
“An Open-Label, Randomized, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Pollux”	American Society of Hematology (ASH) 2016 Symposium on Hematologic Malignancies, Chicago, IL	September 2016
“An Open-Label, Randomized, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Pollux”	American Society of Hematology (ASH) 2016 Annual Meeting, San Diego, CA	December 2016
“Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)”	American Society of Hematology (ASH) 2016 Annual Meeting, San Diego, CA	December 2016
“Optimal Management of Young, Transplant Eligible Newly Diagnosed Multiple Myeloma”	Educational Session, American Society of Hematology Annual Meeting, San Diego, CA.	December 2018
“Monoclonal Antibody Based Induction in Newly Diagnosed Multiple Myeloma”	Educational Session, American Society of Clinical Oncology Annual meeting, Chicago, IL	June 2019
Late Breaking Abstract titled “Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)”.	American Society of Hematology 2019 Annual Meeting, Orlando, FL	2019

Oral Abstract Presentation titled “Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211)”	American Society of Clinical Oncology (ASCO) 2020 Annual Virtual Meeting	May 2020
Oral Abstract Presentation titled “Phase 1 study of teclistamab, a humanized B cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM)”	American Society of Clinical Oncology (ASCO) 2020 Annual Virtual Meeting	May 2020
Oral Abstract Presentation titled “Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211)”	EHA 2020 Annual Virtual Meeting	June 2020

### International

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
“Multiple Myeloma Diagnosis, Prognosis & Management”	Department of Medical Oncology, Jinnah Hospital & Allama Iqbal Medical College (JH/AIMC), Lahore, Pakistan	<i>January 2012</i>
“Biologic Basis for Classifying Hematologic Malignancies”	Allama Iqbal Medical College (AIMC), Lahore, Pakistan	<i>January 2012</i>
“New Imaging in Myeloma-Role of MRI and PET”	International Myeloma Working Group Summit 2012, Amsterdam, Netherlands.	June 2012
“Long-term Sequelae of Myeloma Therapy”	4 <sup>th</sup> International Congress on Leukemia, Lymphoma, Myeloma, Istanbul, Turkey.	<i>May 2013</i>
“Highlights of Myeloma Oral Abstracts”	ASCO 2014 Annual Meeting, Chicago, IL	<i>June 2014</i>
“Updated Genetic Risk-stratification of Multiple Myeloma: Can treatment be individualized”	International Myeloma Working Group Summit, Milan, Italy	<i>June 2014</i>
“Emerging Paradigms in Management of Multiple Myeloma”	Japanese Society of Hematology Session, ASH 2014 Meeting San Francisco, CA	<i>December 2014</i>
“Role of Transplant and Maintenance in Multiple Myeloma”	Multiple Myeloma Russian Expert Council. National Hematology Society/Russian Myeloma Working Group, Moscow, Russia	<i>December 2014</i>
“Emerging Paradigms in Management of Multiple Myeloma.”	Japanese Society of Hematology Luncheon at the ASH 2014 Annual Meeting, San Francisco, CA	<i>December 2014</i>
“Are We Ready for Biomarker Driven Therapy in Multiple Myeloma”	ASCO Annual Meeting, Chicago, IL	<i>June 2015</i>
“Optimal Management of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients”	International Multiple Myeloma Symposium, Tokyo, Japan	<i>September 2015</i>
“Updates on Treatment of Relapsed/Refractory Multiple Myeloma”	MMRF ASH 2015 Friday Satellite Symposium	<i>December 2015</i>

“Treatment of Transplant Ineligible Newly Diagnosed Multiple Myeloma”	Japanese Society of Myeloma Annual Meeting 2016, Yokohama; Japan	May 2016
“Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma”	Japanese Society of Hematology Annual Meeting, Yokohama, Japan	October 2016
“What Can We Learn from Long-Term Survivors in Myeloma?”	6th Heidelberg Myeloma Workshop, University of Heidelberg, Germany	April 2017
“Plasma Cell Leukemia”	Controversies in Myeloma 2017, Paris, France	May 2017
“Importance of Depth of Response and MRD Assessment in Myeloma”	Myeloma Forum 2017, Dubai, UAE	May 2017
“How to Treat HighRisk Multiple Myeloma”	International Myeloma Working Group Summit, Madrid, Spain	June 2017
“Landscape of Therapy in Multiple Myeloma”	European Hematology Association Annual Meeting Satellite Symposium on Immunology in Hematologic Malignancies, Madrid, Spain	June 2017
“PET and MRI in Myeloma”	Myeloma 2017, Edinburgh, Scotland	October 2017
“Extramedullary Multiple Myeloma” & “Debate: Case for Monoclonal Antibodies for Relapsed MM”	Controversies in Myeloma 2018, Paris	May 2018
“Managing Newly Diagnosed Multiple Myeloma”	43rd Annual Meeting, Japanese Society of Myeloma	May 2018
“Monoclonal Antibodies in Multiple Myeloma”	European Society of Hematology Annual Meeting, Mandelieu, France	September 2018
“Phase 3 Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Vs. Rd in Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): MAIA**”	Plenary Session, Japanese Society of Myeloma Annual Meeting, Nagoya, Japan.	May 2019
“Incorporating Geriatric Assessments for Elderly Multiple Myeloma Patients”	Educational Session, Japanese Society of Myeloma Annual Meeting, Nagoya, Japan	May 2019
“Are We Ready to Personalize Therapy in Myeloma, Yes or No?”	Controversies in Myeloma Congress, Paris, France	May 2019
“Emerging Immunotherapies in Multiple Myeloma” and “CART Cell Therapy for Multiple Myeloma”	H3 Hematology Symposium, Melbourne, Australia	May 2019
“Monoclonal Antibody-based Induction Regimens for Newly Diagnosed Multiple Myeloma”	ASCO Annual Meeting Educational Session, Chicago, IL	June 2019
“Managing Myeloma in First Relapse”	HEMO-2019 Meeting, Rio de Janeiro, Brazil	November 2019
“Managing Relapsed/Refractory Multiple Myeloma”	Controversies in Myeloma Congress, France	May 2020
“Immunotherapy for Multiple Myeloma”	ASCO Annual Meeting 2020 Virtual Symposium	June 2020
“Taking a ‘BiTE’ out of Multiple Myeloma”		
Meet the Professor Session “Managing High Risk Multiple Myeloma”	5th European School of Hematology Translational Research in Myeloma Conference	September 2020
“Options beyond 2nd Line in Multiple Myeloma”		
“Bispecific Antibodies in Multiple Myeloma”	International Myeloma Working Group Virtual Summit	September 2020

## S. BIBLIOGRAPHY

### 1. Peer-reviewed Research Articles:

1. **Usmani SZ**, Shahid Z. An Overview of Postmenopausal Osteoporosis. Pak J Med Sci, July-Sept2004; 20; 270-5
2. Merajver SD, **Usmani SZ**. Multifaceted role of Rho proteins in angiogenesis. J Mammary Gland BiolNeoplasia. 2005; 10:291-8. PMID:16900393
3. Halaweh O, **Usmani SZ**, Bloom R. Chemotherapy Induced Thymus Hyperplasia Mimics Recurrence of Cancer. Breast J. 2006; 12:381-2. PMID:16848854
4. Yunus SA, **Usmani SZ**, Ahmed S, Shahid Z. Renal Involvement in Non-Hodgkin's lymphoma-theShaukat Khanum experience. Asian Pac J Cancer Prev. 2007; 8:249-52. PMID:17696740
5. **Usmani SZ**, Shahid Z, Nasser K. J Nephrol. A rare case of postinfectious glomerulonephritis caused by pneumococcus in an adult patient. J Nephrol 2007; 20:99-102. PMID:17347982
6. Halaweh O, **Usmani SZ**, Abouasaleh R. Barrett's Esophagitis Related Tracheoesophageal Fistula-The Diagnostic Value of Persistent Air Leak in the Ventilated Setting. McGill J Med. 2007; 10:96-8
7. **Usmani SZ**, Shahid Z, Saleh H, Nasser KA. Myeloid sarcoma presenting as acute renal failure andbilateral ureteral obstruction- a very rare presentation. Am J Med Sci. 2007; 334:136-8. PMID:17700206
8. **Usmani SZ**, Sahay T, Eisenberg L. Angioimmunoblastic T-cell lymphoma in evolution- a case report. Adv Ther. 2007; 24: 814-8
9. **Usmani SZ**, Ding L, Abu-Rashed AH, Saleh HA. Duodenal MALT lymphoma presenting with obstructive jaundice: report of a case and review of the literature. J Gastrointest Cancer. 2007; 38:28 -31. PMID:19065720
10. **Usmani SZ**, Appel J, Shahid Z, Saleh H. Spontaneous Tumor Lysis Syndrome and Secondary Thrombotic Thrombocytopenic Purpura in Early-Stage Colorectal Cancer. Chin J of Clin Oncol. 2008;5:150-3
11. Sharma R, **Usmani SZ**, Siegel R. Primary Squamous Cell Carcinoma of breast in background of Phyllodes tumor- A Case Report. Conn Med. 2009; 73:341-3. PMID:19637664
12. **Usmani SZ**, Bona RD, Li Z. 17-AAG: From bench to bedside. Curr Mol Med. 2009; 9:654-64. PMID:19601813
13. **Usmani S**, Pazooki M, Bilgrami SF. Small Cell Carcinoma of the Gall Bladder: Role of AdjuvantTherapy. J Gastrointest Cancer 2010; 41:84-7. PMID:20063076
14. Jabbour N, DiGiuseppe JA, **Usmani S**, Tannenbaum S. Copper deficiency as a cause of reversible anemia and neutropenia. Conn Med. 2010;74(5):261-3. PMID:20509415
15. **Usmani SZ**, Tannenbaum S, Hegde P. Emperipolesis in Giant Cell Carcinoma of the Lung. CommOncol 2010; 7:233–235.
16. **Usmani SZ**, Yunus SA, Jamal Y. Overview of CML in Pakistan in the pre-Imatinib era. Asian Pac JCancer Prev 2010; 10;1039-1040. PMID:20192579
17. **Usmani SZ**, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol. 2010; 3:40. PMID:20977755
18. **Usmani SZ**, Sexton R, Crowley J, Barlogie B. Autologous Stem Cell Transplantation as a Care Option for Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:139-42. PMID:21454216
19. Shaughnessy J, Qu P, **Usmani SZ**, Tian E, VanRhee F, Anaissie E, Nair B, Waheed S, AISayed Y, Crowley J, Barlogie B. High PSMD4 Expression Levels in Plasma Cells Identified via Bortezomib Test -Dosing are Linked to Poor Prognosis in Untreated Multiple Myeloma. Blood 2011; 118:3512

-24. PMID:21628408

20. **Usmani SZ**, Chiosis G, Bona RD. HSP90 Inhibitors as Therapy for Multiple Myeloma. *ClinLymphoma Myeloma Leuk* 2011; S1;77-81. PMID:22035754
21. Papanikolaou X, Barlogie B, **Usmani SZ**. Therapy-related Myeloid Malignancies in Myeloma. *Mediterr J Hematol Infect Dis* 2011, 3: e2011047. PMID:22110897
22. Ahmed N, **Usmani SZ**, Jabbour N, Hegde U. Acute Psychosis After Paclitaxel Infusion. *Conn Med*. 2011; 75:465-466. PMID:21980675
23. Muzaffar J, Katragadda L, Javed A, Restrepo A, Grazzuitti M, Anaissie E, **Usmani SZ**. Rituximab and Intravenous immunoglobulin (IVIg) for the management of Acquired Factor VIII Inhibitor in Multiple Myeloma: case report and review of literature. *Int J Hematol*. 2012; 95(1):102-6. PMID:22170228
24. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, **Usmani S**, Einsele H, Comenzo R, Orłowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. *IMWG Guidelines. Leukemia*. 2012;26(4):595-608. PMID:22193964
25. **Usmani SZ**, Nair B, Qu P, Hansen E, Petty N, Zhang Q, Waheed S, Shaughnessy JD, Alsayed Y, Heuck CJ, Van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Swayer J, Losbach R, Crowley J, Barlogie B. Primary Plasma Cell Leukemia: Clinical and Laboratory Presentation and Clinical Outcome with Total Therapy Protocols. *Leukemia*. 2012;26(11):2398-405. PMID:22508408
26. **Usmani SZ**, Sexton R, Hoering A, Heuck C, Nair B, Waheed S, AlSayed Y, Petty N, Crowley J, Barlogie B. Second Malignancies in Total Therapy Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases. *Blood*. 2012 Aug 23;120(8):1597-600. PMID:22674807
27. **Usmani SZ**, Mitchell A, Szymonifka J, Qu P, Weed M, Shaughnessy J, Nair B, Waheed S, AlSayed Y, Crowley J, Barlogie B. Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Overrepresented In High Risk Disease in the Era of Novel Agents. *Haematologica*. 2012; 97(11):1761 -7. PMID:22689675
28. Heuck C, Szymonifka J, Hansen E, Shaughnessy JD, **Usmani S**, Van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley JJ, Barlogie B. Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1. *Clin Cancer Res*. 2012;18(19):5499-506. PMID:22855579
29. Singh Z, Medlin S, **Usmani SZ**. Molecular monitoring and treatment of Chronic Myeloid Leukemia. *Clin Exp Pathol* 2012,2;4. doi.org/10.4172/2161-0681.1000113
30. Chauhan N, Barlogie B, **Usmani SZ**. Impediments to Curing Multiple Myeloma in the Year 2012. *Int J Hematol Oncol* 2012;1(1): 29-34.
31. Latif T, Chauhan N, Khan R, Moran A, **Usmani SZ**. Thalidomide and its analogues in the treatment of Multiple Myeloma. *Exp Hematol Oncol*. 2012 Sep 11;1(1):27. doi: 10.1186/2162-3619-1-27. PMID:23210501
32. Muzaffar J, Katragadda L, Haider S, Abdallah A, Anaissie E, **Usmani S**. Waldenstrom's Macroglobulinemia Associated with Serum Amyloid A protein (SAA) Amyloidosis: Pitfalls in Diagnosis and Successful Treatment with Melphalan-based Auto Stem Cell Transplant. *Acta Haematol*. 2013 May9;130(3):146-149. PMID:23689541
33. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, **Usmani S**, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, Leleu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orłowski RZ, Shah JJ. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*. 2013 Apr;27(4):780-91. PMID:23288300
34. Waheed S, Mitchell A, **Usmani S**, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T,

- Bartel T, McDonald J, Anaissie E, van Rhee F, Shaughnessy JD, Crowley J, Barlogie B. Standard and novel imaging methods for multiple myeloma correlates with prognostic laboratory variables including gene expression profiling data. *Haematologica*. 2013 Jan;98(1):71-8. PMID:22733020
35. Muzaffar J, **Usmani S**, Abdallah A, Anaissie E, Cotler-Fox M, Restrepo A. High dose chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma in HIV positive patients in the Highly Active Antiretroviral Therapy era- the Myeloma Institute of Research and Therapy experience *Clin Lymphoma Myeloma Leuk*. 2013 Apr;13(2):171-4. PMID:23313066
  36. **Usmani SZ**, Crowley J, Hoering A, Sexton R, Waheed S, Nair B, AlSayed Y, van Rhee F, Barlogie B. *Improvement in Long Term Outcomes with Successive Total Therapy Trials for Multiple Myeloma: Are Patients Now Being Cured? Leukemia*. 2013;27(1):226-32. PMID:22705990
  37. **Usmani SZ**, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, van Rhee F, Barlogie B. 18-FDG PET Focal Lesion and Avidity Suppression After Induction Therapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma. *Blood*. 2013 Mar 7;121(10):1819-23. PMID:23305732
  38. Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, **Usmani S**, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. *Exp Hematol*. 2013;41(6):547-557. PMID:23435312
  39. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, **Usmani S**, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of bruton's tyrosine kinase (BTK) in myeloma cell migration and clonogenicity, and induction of bone disease. *Am J Hematol*. 2013;88(6):463-71. PMID:23456977
  40. **Usmani SZ**, Rosenthal A, Sexton R, Hoering A, Singh Z, Heuck C, Medlin S, Waheed S, Chauhan N, Abdullah A, Muzaffar J, Petty N, Crowley, Sawyer J, Barlogie B. Risk Factors for MDS and Acute Leukemia Following Total Therapy 2 and 3 for Multiple Myeloma: Contributions of Therapy, Patient and Myeloma Features. *Blood* 2013;121(23):4753-7. PMID:23603914
  41. Ahmed N, Haider S, Jameel M, Shahid Z, Yared M, **Usmani SZ**. Anti-Myelin Associated Glycoprotein Polyneuropathy in a Patient with Lymphoma and its Resolution After Chemotherapy. *J Med Cases* 2013;4(8):557-55.
  42. Atrash S, Aziz B, Papanicolaou X, Abdalla A, Muzaffar J, Kumar S, Waheed S, Van Rhee F, **Usmani SZ**, Barlogie B. Metronomic Therapy for Multi Relapsed/Refractory Lymphoma: A Pilot Study. *Current Angiogenesis*. 2013;2(2):119-125.
  43. Razavi P, Rand KA, Cozen W, **Usmani SZ**, Sher T, Chanan-Khan A, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. *Blood Cancer J*. 2013 Jun 28;3: e121. doi: 10.1038/bcj.2013 PMID:23811785
  44. Kurzrock R, Vorhees PM, Casper C, Furman R, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, **Usmani SZ**, van de Velde H, Qin X, Cornfeld MJ, van Rhee F. Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. *Clin Cancer Res* 2013; 19(13):3659-3670. PMID:23659971
  45. Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D, Keller J, Waheed S, **Usmani SZ**, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B. Metronomic Therapy Is an Effective Salvage Treatment for Heavily Pretreated Relapsed/Refractory Multiple Myeloma. *Hematologica* 2013;98(7):1147-53. PMID:23716540
  46. Chen Y, Hu B, **Usmani SZ**, Papanikolaou X, Heuck C, Epstein J, Barlogie B, Qing Y. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. *PLoS One*. 2013;8(9): e74191. doi: 10.1371/journal.pone.0074191. PMID:24066119
  47. Abuabdou A, Rosenbaum ER, **Usmani SZ**, Barlogie B, Cotler-Fox M. Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. *J Clin Apher*. 2014 Oct;29(5):251-5. PMID:24347510
  48. Hua Y, White-Gilbertson S, Kellner J, Rachidi S, **Usmani SZ**, Chiosis G, DePinho R, Li Z, Liu B. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. *Clin Cancer Res*. 2013 Nov 15;19(22):6242-51 PMID:24077352

49. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, **Usmani S**, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim J, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, San Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia* 2014; 28(3):525-42. PMID:24253022
50. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palimbo A, San Miguel J, Sonneveld P, **Usmani S**, Durie BGM, Avet-Loiseau H. IMWG Consensus on Risk Stratification in Multiple Myeloma. *Leukemia*. 2014;28(2):269-77. PMID:23974982
51. Abdallah A, Atrash S, Shahid Z, Jameel M, Graziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck C, Johann D, Barlogie B, **Usmani SZ**. Patterns of CNS Involvement in Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2014;14(3):211-4. PMID:24373936
52. Hamadani M, Abu Kar SM, **Usmani SZ**, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. *Semin Hematol*. 2014;51(1):73- 86. PMID:24468319
53. Dhodapkar M, Sexton R, Waheed S, **Usmani S**, Papanikolaou X, Petty N, Nair B, Shaughnessy J, Hoering A, Crowley J, Orlowski R, Barlogie B. Clinical, Genomic and Imaging Predictors of Myeloma Progression from Asymptomatic Monoclonal Gammopathies (SWOG S0120). *Blood*. 2014;123(1):78-85. PMID:24144643
54. Sawyer SR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Litchi - Binz R, Boast A, Sammartino G, **Usmani S**, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping Translocations of 1q12 in Multiple Myeloma: A Novel Mechanism for Deletion of 17p in Cytogenetically Defined High-Risk Disease. *Blood*. 2014;123(16):2504-12. PMID:24497533
55. Palumbo A, Brinchen S, Rajkumar V, Luparelli G, **Usmani S**, Waage A, Larocca A, van der Holt B, Musto P, Evangelista A, Zweegman S, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Barlogie B, Sonneveld P, McCarthy P. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol*. 2014;15(3):333-42. PMID:24525202
56. Heuck CJ, Qu P, van Rhee F, Waheed S, **Usmani SZ**, Epstein J, Zhang Q, Hoering A, Croely J, Barlogie B. Five gene probes carry most of the discriminatory power of the 70 -gene risk model in multiple myeloma. *Leukemia*. 2014 ;28(12):2410-3. PMID:25079174
57. **Usmani SZ**, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, van Rhee F, Crowley J, Barlogie B. Phase II Trial of Pomalidomide in High Risk Relapsed and Refractory Multiple Myeloma. *Leukemia*. 2014;28(12):2413-5. PMID:25151956
58. **Usmani SZ**, Lonial S. Novel Drugs Combinations for the Management of Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2014; 14S:S71-S77. PMID:25486960
59. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, **Usmani SZ**, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014 Nov;15(12):e538-e548. PMID:25439696
60. Atrash S, Tullos A, Panosso S, Bhutani M, Van Rhee F, Barlogie B, **Usmani SZ**. Cardiac complications in relapsed and refractory multiple myeloma patients treated with Carfilzomib. *Blood Cancer J*. 2015 Jan 16;5: e272. doi: 10.1038/bcj.2014.93. PMID:25594159
61. Khan R, Apewokin S, Graziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, **Usmani S**, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD, Barlogie B. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. *Leukemia*. 2015 May;29(5):1195-201. PMID:25640885
62. Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, **Usmani SZ**, Bailey C,



- Petty N, Van Rhee F, Barlogie B. Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. *Clinical Case Reports* 02/2015; DOI: 10.1002/ccr3.180.
63. Dimopoulos M, Hillengass J, **Usmani S**, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E. The Role of Magnetic Resonance Imaging in the Management of Patients with Multiple Myeloma: a Consensus Statement on behalf of the IMWG. *J Clin Oncol.* 2015 Feb 20;33(6):657-64. PMID:25605835
  64. Arikian SZ, Milentijevic D, Binder G, Monzini MS, Hu H, Nagarwala Y, Hussein M, Corvino FA, Surinach A, **Usmani SZ**. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. *Curr Med Res Opin.* 2015 Mar 18;1-33. PMID:25785551
  65. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfani-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, **Usmani SZ**, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors. *Biol Blood Marrow Transplant.* 2015 Aug 4. pii: S1083-8791(15)00505-4. doi: 10.1016/j.bbmt.2015.07.028. [Epub ahead of print]. PMID: 26253007
  66. **Usmani SZ**, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Phase I Safety Data of Lenalidomide, Bortezomib, Dexamethasone, and Elotuzumab as Induction Therapy for Newly Diagnosed Symptomatic Multiple Myeloma: SWOG S1211. *Blood Cancer J.* 2015 Aug 7;5:e334. doi: 10.1038/bcj.2015.62. PMID: 26252787
  67. Bhutani M, Landgren O, **Usmani SZ**. Multiple Myeloma: Is It Time for Biomarker-Driven Therapy? *Am Soc Clin Oncol Educ Book.* 2015;35: e493-503. doi: 10.14694/EdBook\_AM.2015.35. e493. PMID: 25993214
  68. **Usmani SZ**, Rodreguez-Otero P, Bhutani M, Mateos MV, San Miguel J. Defining and treating high-risk multiple myeloma patients: a clinical challenge. *Leukemia.* 2015 Nov;29(11):2119-25. PMID:26265183
  69. Giral S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Jin L, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Rivas E, San Miguel J, Tureson I, **Usmani S**, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant.* 2015 Aug 4. pii: S1083-8791(15)00505-4. doi: 10.1016/j.bbmt.2015.07.028. [Epub ahead of print] PMID: 26253007
  70. Klyuchnikov E, Bacher U, Ahn KW, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfani-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schoten HC, **Usmani SZ**, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. *Bone Marrow Transplant.* 2016 Jan;51(1):58-66. PMID: 26437062
  71. Hidayat AN, Aki-Yalcin E, Beksac M, Tian E, **Usmani SZ**, Ertan-Bolelli T, Yalcin I. Insight into human protease activated receptor-1 as anticancer target by molecular modelling. *SAR QSAR Environ Res.* 2015 Oct 26;1-13. PMID: 26501801

- 72 . **Usmani SZ**, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Marek J, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson C, Facon T. Cost - Effectiveness of Lenalidomide plus Dexamethasone Versus Bortezomib plus Melphalan and Prednisone in Transplant -ineligible Patients with Newly Diagnosed Multiple Myeloma. *J Med Econ*. 2015 Oct 30;1-42. [Epub ahead of print] PMID: 26517601
73. Chng WJ, Chung TH, Kumar S, **Usmani SZ**, Munshi N, Avet-Loiseau A, Goldshmidt H, Durie B, Sonneveld P, et al. Gene Signature Combinations Improve Prognostic Stratification of Multiple Myeloma Patients. *Leukemia*. 2016 May;30(5):1071-8. PMID:26669975
74. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tajeja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maricl, **Usmani SZ**, Choyke PL, Kurdziel K, Landgren O. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: A prospective study using functional and morphologic imaging. *Leuk Lymphoma*. 2015 Dec 21:1-23. [Epub ahead of print] PMID: 26690712
75. Lonial S, Weiss B, **Usmani SZ**, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial. *Lancet* 2016 DOI: [http://dx.doi.org/10.1016/S0140-6736\(15\)01120-4](http://dx.doi.org/10.1016/S0140-6736(15)01120-4)
76. Chow E, Shahid Z, Smith ET, Kamionek M, **Usmani SZ**. Successful treatment of hepatitis C infection while receiving concurrent chemotherapy for AL Amyloidosis. *Clin Lymphoma Myeloma Leuk*. 2016 Jan 18. pii: S2152-2650(16)00022-7. doi: 10.1016/j.clml.2016.01.003. PMID: 26869507
77. Jurczynski A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Diaz AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzdzitek A, Walewski J, Corso A, Cocito F, Vekemans MM, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska- Zubkiewicz L, **Usmani S**, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierzczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. *Am J Hematol*. 2016 Jun;91(6):575-80.. PMID: 26955792
78. Zhang XD, Baladanayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, **Usmani SZ**, Zhang Q, Crowley J, Hoering A, Li BZ, Wang HH, Zhang J, Kuitse I, Tang JL, Wang H, Jin H, Yang J, Milan E, Cenci S, David RE, Ma WC, Wang ZQ, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma Through EGFR/JAK1/STAT3 Signaling. *Cancer Cell*. 2016 Apr 26. pii: S1535- 6108(16)30109-X. doi: 10.1016/j.ccell.2016.03.026. [Epub ahead of print] PMID: 27132469
- 79 . Sonneveld P, Avet-Loiseau, Lonial S, **Usmani SZ**, Siegel DS, Anderson KC, Chng WJ, Moreau, Attal M, Kyle RA, Caers J, Hillengass J, Can Miguel JF, van de Donk N, Einsele H, Blade J, Durie B, Goldshmidt H, Mateos MV, Palumbo A, Orlowski RZ. Treatment of Multiple Myeloma with high-risk *cytogenetics*: A consensus of the *International Myeloma Working Group*. *Blood* 2016 Mar 21. pii: blood-2016-01-631200. PMID: 27002115
80. Bhutani M, Shahid Z, Schnebeln A, Alapat D, **Usmani SZ**. Skin Problems in Multiple Myeloma and Other Plasma Cell Proliferative Disorders. *Semin Oncol*. 2016 Jun;43(3):395 - 400. doi: 10.1053/j.seminoncol.2016.02.017. Epub 2016 Feb 23. PMID: 27178694
81. **Usmani SZ**, Weiss B, Bahlis N, Belch A, Lonial S, Lokhorst H, Voorhees P, Richardson PG, Sasser AK, Axel A, Feng H, Uhlar C, Wang J, Khan I, Ahmadi T, Nahi H. Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. *Blood* 2016;128(1):37-44. PMID:27216216
82. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J,

- Mateos MV, Dimipolous M, Kastritis E, Boccadoro M, Orlowski R, Goldshmidt H, Spencer A, Hou J, Chng WJ, **Usmani SZ**, Zagmani E, Shimizu K, Jagganath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson P, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajukar SV, San Miguel J, Avet-Loiseau H. International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma. *Lancet Oncol*. 2016 Aug;17(8): e328-46. doi: 10.1016/S1470-2045(16)30206-6. PMID: 27511158
83. **Usmani SZ**, Ahmadi T, Ng Y, Lam A, Deasi A, Potluri, Mehra M. Analysis of Real-world Data on Overall Survival in Multiple Myeloma Patients with 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD. *Oncologist*. 2016 Nov;21(11):1355-1361. PMID: 27486203
  84. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, **Usmani S**, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared to Non-High Risk Multiple Myeloma, a CIBMTR Analysis. *Biol Blood Marrow Transplant*. 2016 Aug 2. pii: S1083-8791(16)30223-3. doi: 10.1016/j.bbmt.2016.07.007. [Epub ahead of print] PMID:27496215
  85. Dimopolous M, Oriol A, Nahi H, San Miguel J, Bahlis NJ, **Usmani SZ**, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Lisby L, Khokhar NZ, O'Rourke L, Chiu c, Qin X, Guckert M, Ahmadi T, Moreau P. Daratumumab, Lenalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma. *N Eng J Med* 2016 Oct 6;375(14):1319-1331. PMID: 27705267
  86. Voorhees PM, **Usmani SZ**. The role of high dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. *Clin Adv Hematol Oncol*. 2016 Sep;14(9):719-728.
  87. Jacobs RW, Awan FT, Leslie LA, **Usmani SZ**, Ghosh N. The Shrinking Role of Chemotherapy in the Treatment of Chronic Lymphocytic Leukemia. *Expert Rev Hematol*. 2016 Dec;9(12):1177-1187. PMID: 27791448
  88. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, **Usmani S**, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma. *Biol Blood Marrow Transplant*. 2016 Oct 24. pii:S1083-8791(16)30424-4. doi: 10.1016/j.bbmt.2016.10.010. [Epub ahead of print] PMID: 27789362
  89. Norris EJ, DeStephanis D, Tunquist B, **Usmani S**, Ganapathi R, Ganapathi M. Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells. *Blood Cancer J*. 2016 Oct 7;6(10): e480. doi: 10.1038/bcj.2016.92. PMID: 27716742
  90. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BG, Miguel JS, Einsele H, Chen WM, Garderet L, Pietrantonio G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Serra ER, Sezer O, Terpos E, Turesson I, **Usmani S**, Weiss BM, Palumbo A. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. *Ann Oncol* . 2017 Feb 1;28(2):228-245. PMID: 27864218
  91. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, **Usmani S**, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2017 Feb;23(2):269- 277. PMID: 27864161

92. Agarwal A, Chow E, Bhutani M, Voorhees P, **Usmani SZ**. Practical Consideration in Managing Relapsed Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2017 Feb;17(2):69-77. PMID: 27986429
93. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, **Usmani SZ**, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orłowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BG, Zamagni E. Role of 18F-FDG Positron Emission Tomography/Computed Tomography in the diagnosis and management of multiple *myeloma and other plasma cell dyscrasias: a consensus statement by the International Myeloma Working Group*. *Lancet Oncol*. 2017 Apr;18(4): e206-e217. PMID: 28368259
94. Friend R, Bhutani M, Voorhees PM, **Usmani SZ**. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma. *Drug Des Devel Ther*. 2017 Mar 20; 11:893-900. doi: 10.2147/DDDT.PMID: 28356715
95. **Usmani SZ**, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab Monotherapy Compared with Historical Control Data in Heavily Pretreated and Highly Refractory Patients with Multiple Myeloma: An Adjusted Treatment Comparison. *Am J Hematol*. 2017 Aug;92(8):E146-E152. PMID: 28474745
96. Schriber J, Hari P, Ahn KW, Fei M, Costa L, Kharfan-Dabaja MA, Diaz MA, Gale RP, Ganguly S, Girnius S, Hashmi S, Pawarode A, Vesole D, Weirnik PH, Wirk B, Marks DI, Nishihori T, Olsson R, **Usmani SZ**, Mark T, Nieto YL, D'Souza A. Hispanics have the Lowest Stem Cell Utilization Rate for Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in the United States: a CIBMTR Report. *Cancer*. 2017 Aug 15;123(16):3141-3149. PMID: 28472539
97. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van deDonk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, **Usmani SZ**, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*. 2017 Nov;31(11):2443-2448. PMID: 28620163
98. Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, **Usmani SZ**. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. *Lancet Haematol*. 2017 Sep;4(9): e443-e451. doi: 10.1016/S2352-3026(17)30143-6. PMID: 28863804
99. Yan X, Clemens P, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, **Usmani SZ**, Richardson PG, Plesner T, Liu K, Orłowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Perez Ruixo JJ, Zhou K, Xu XS. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. *Clin Pharmacokinet*. 2018 Apr;57(4):529-538. PMID: 28983805
100. Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlir C, Khan I, Doshi P, **Usmani S**. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2018 Jan;18(1):44-51. PMID: 29054515
101. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, **Usmani S**, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. *Leukemia*. 2017 Nov;31(11):2443-2448. PMID: 29263438
102. Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, **Usmani SZ**, Wallace PK, Weisel K, McCarthy PL. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations

- from the Organizing Committee. *Biol Blood Marrow Transplant*. 2018 Apr;24(4):641-648. PMID: 29242112
- 103 . Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, **Usmani SZ**, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Mar 1;4(3):343-350.. PMID: 29302684
- 104 . **Usmani SZ**, Choquette L, Bona R, Feinn R, Shahid Z, Lalla RV. Transient bacteremia induced by dental cleaning is not associated with infection of central venous catheters in patients with cancer. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2018 Apr;125(4):286-294. PMID: 29428697
- 105 . Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan EA, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, **Usmani SZ**, Gasparetto C, Mark TM, Nieto Y, Hari P. Upfront autologous/allogeneic hematopoietic cell transplantation (HCT) versus tandem autologous transplantation for multiple myeloma – Comparison of long-term post relapse survival. *Biol Blood Marrow Transplant*. 2018 Mar;24(3):478-485. PMID: 29079457
- 106 . van Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst H, **Usmani SZ**, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. *Br J Haematol*. 2019 Feb;184(3):475-479.. PMID: 29411874
- 107 . Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, **Usmani SZ**, Anderson LD, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. *Leuk Lymphoma*. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443337.[Epub ahead of print] PMID: 29616843
- 108 . Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, **Usmani SZ**, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: *The Revised International Staging System shows the most Differentiation between Groups*. *Biol Blood Marrow Transplant*. 2018 Aug 21. pii: S1083-8791(18)30478-6. doi: 10.1016/j.bbmt.2018.08.013. PMID: 30142419
- 109 . Dimopoulos MA, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, San-Miguel J, Moreau P, Kaufman JL, Sutherland HJ, Lanacette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Chari A, O'Rourke L, Wu K, Casneuf T, Chiu C, Soong D, Qin X, Sasser AK, Khokar NZ, **Usmani SZ**. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. *Haematologica*. 2018 Dec;103(12):2088-2096. PMID: 30237262
- 110 . van de Donk NWCJ, **Usmani SZ**. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. *Front Immunol*. 2018 Sep 20; 9:2134. doi: 10.3389/fimmu.2018.02134. PMID: 30294326
- 111 . **Usmani SZ**, Hoering A, Cavo M, Miguel JS, Goldschmidt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Clinical Predictors of Long-Term Complete Response in New Diagnosed Multiple Myeloma – an IMWG Research Project. *Blood Cancer J*. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7. PMID: 30470751
- 112 . Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, **Usmani SZ**, Lonche A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. *Cancer*. 2018 Nov 15;124(22):4342-4349. PMID: 30395359
- 113 . Arnall JR, **Usmani SZ**, Adamu H, Mishkin J, Bhutani M. Daratumumab, pomalidomide, and

- dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement. *J Oncol Pharm Pract*. 2018 Nov 26;1078155218815305. doi: 10.1177/1078155218815305. PMID: 30477388
114. Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, **Usmani SZ**, Bhutani M. Evolving changes in M- protein and hemoglobin as predictors for progression of smoldering multiple myeloma. *Blood Cancer J*. 2018 Nov 8;8(11):107. doi: 10.1038/s41408-018-0144-x. PMID: 30410066
115. Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, **Usmani SZ**. Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. *Biol Blood Marrow Transplant*. 2018 Nov 24. pii: S1083-8791(18)30748-1. doi: 10.1016/j.bbmt.2018.11.015.[Epub ahead of print] PMID: 30481597
116. **Usmani SZ**, Seifter E. Treatment approach for young, fit, newly diagnosed multiple myeloma patients. *Hematology Am Soc Hematol Educ Program*. 2018 Nov 30;2018(1):97 - 102. doi: 10.1182/asheducation-2018.1.97. PMID: 30504297
117. Adams HC 3rd, Stevenaert F, Krejci J, Van der Borgh K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, **Usmani SZ**, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. *Cytometry A*. 2019 Mar;95(3):279-289. PMID: 30536810
118. Copelan O, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, Jacobs R, Knight TG, **Usmani SZ**, Grunwald MR, Ghosh N, Symanowski JT, Shahid Z, Clark PE, He J. Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related Donor Transplantation. *Biol Blood Marrow Transplant*. 2018 Dec 20. pii: S1083 - 8791(18)30964-9. PMID: 30579967
119. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, **Usmani SZ**, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised - International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM). *Biol Blood Marrow Transplant*. 2018 Dec 20. pii: S1083-8791(18)30963-7. PMID: 305799657
120. van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, **Usmani SZ**, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. *Br J Haematol*. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. PMID: 29411874
121. Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, Yusuf AA, **Usmani SZ**. Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. *J Geriatr Oncol*. 2019 Jan 29. pii: S1879-4068(18)30311-4. doi: 10.1016/j.jgo.2019.01.007. PMID: 30709612
122. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, **Usmani SZ**, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019 Sep;33(9):2266-2275. PMID: 30858549
123. Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, **Usmani SZ**. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. *Leuk Lymphoma*. 2019 Mar 8;1-4. doi: 10.1080/10428194.2019.1576871. PMID: 30848971
124. Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, **Usmani SZ**,

- Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, StullDM, Hungria V. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. *Future Oncol*. 2019 Feb 28. doi: 10.2217/fon-2019-0013. PMID: 30816809
125. Mikhael J, Richardson P, **Usmani SZ**, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K. A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Blood*. 2019 Mar 12. pii: blood-2019-02-895193. PMID: 30862646
126. Facon T, Kumar SK, Plesner T, Orlowski RO, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Ahmadi T, Chiu C, Wang J, Van Rempelbergh R, Uhlar C, Kobos R, Qi M, **Usmani SZ**. Daratumumab, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma. *N Engl J Med*. 2019 May 30;380(22):2104- 2115. doi: 10.1056/NEJMoa1817249. PMID: 31141632
127. **Usmani SZ**, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Ming Lim AB, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori R, Farooqui MZH, Marinello P, San-Miguel J. Pembrolizumab, lenalidomide and dexamethasone for multiple myeloma. *Lancet Haematol*. 2019 Jul 18. pii: S2352 -3026(19)30109-7. doi:10.1016/S2352-3026(19)30109-7. PMID: 31327689
128. Mateos MV, Blacklock H, Schjesvold F, Rocafiguera AO, Simpson D, George A, Goldschmidt H, Larocca A, Sherbenou DW, Avivi I, Iida S, Matsumoto M, **Usmani SZ**, Jagannath S, Lonial S, Rodriguez-Otero P, Kher U, Farooqui MZH, Liao J, Marinello P, Lonial S. Pembrolizumab Plus Pomalidomide and Dexamethasone in Multiple Myeloma. *Lancet Haematol*. 2019 Jul 18. pii: S2352 -3026(19)30110-3. doi: 10.1016/S2352-3026(19)30110-3. PMID: 31327687
129. Paul B, Lipe B, Ocio EM, **Usmani SZ**. Induction Therapy for Newly Diagnosed Multiple Myeloma. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39: e176-e186. doi: 10.1200/EDBK\_238527. Epub 2019 May17. PMID: 31099624
130. Hillengass J, **Usmani SZ**, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Serra ER, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasmacell disorders. *Lancet Oncol*. 2019 Jun;20(6): e302-e312. PMID: 31162104
131. **Usmani SZ**, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellems P, Masterson T, Clemens PL, Luo M, Liu K, San Miguel J. Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma. *Blood*. 2019 Aug 22;134(8):668-677. PMID: 31270103
132. Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, **Usmani SZ**, Ford P. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2019 Jul 8. pii: S1083- 8791(19)30435-5. doi: 10.1016/j.bbmt.2019.07.003. PMID: 31295572
133. **Usmani SZ**, Shah J, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R. Oprozomib, pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2019 May 29. pii: S2152 - 2650(19)30108-9. doi: 10.1016/j.clml.2019.05.017. PMID: 31326409
134. Lonial S, Lee HC, Badros A, Trudel S, Nooka AJ, Chari A, Abdallah A, Callandar N, Lendvai N, Sborov D, Suvannasankha A, Weise K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortum KM, Rodriguez-Otero P, **Usmani SZ**, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Choen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomized, open-label, phase 2 study *Lancet Oncol* . 2020 Feb;21(2):207-221. PubMed PMID:31859245.
135. Bhutani M, Foureau DM, Atrash S, Voorhees PM, **Usmani SZ**. Extramedullary multiple myeloma. *Leukemia* 2020;34(1):1-20. PubMed PMID: 31776467.



- 136 . Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, **Usmani SZ**, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. *Haematologica*. 2020 Jan 31;105(2):468-477. doi:10.3324/haematol.2019.217448. PubMed PMID: 31221782.
- 137 . Shah N, Chari A, Scott E, Mezzi K, **Usmani SZ**. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia*. 2020 Apr;34(4):985-1005. PubMed PMID: 32055000.
- 138 . Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, **Usmani SZ**, Anderson LD Jr, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. *Hematol Oncol*. 2020 Aug;38(3):353-362. PMID: 32053229.
- 139 . Xu XS, Moreau P, **Usmani SZ**, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. *Adv Ther*. 2020 Feb 20. doi: 10.1007/s12325-020-01247-8. PubMed PMID: 32078124.
- 140 . Jagosky MH, **Usmani SZ**. Extramedullary Disease in Multiple Myeloma. *Curr Hematol Malig Rep*. 2020 Mar 20. doi: 10.1007/s11899-020-00568-3. PMID: 32198576
- 141 . Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampur DA, Yuan Z, Xu S, Qi M, **Usmani SZ**. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial. *Lancet Haematol*. 2020 May;7(5): e370-e380. doi: 10.1016/S2352-3026(20)30070-3. PMID: 32213342
- 142 . San-Miguel J, **Usmani SZ**, Mateos MV, van de Donk NWCJ, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Liu K, Hellemans P, Masterson T, Clemens PL, Luo M, Farnsworth A, Nahi H, Chari A. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). *Haematologica*. 2021 Jun 1;106(6):1725-1732. PMID: 32354874
- 143 . Casneuf T, Adams HC 3rd, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, Van der Borght K, Smets T, Foulk B, Nielsen KC, Rusbuldt J, Axel A, Lysaght A, Ceulemans H, Stevenaert F, **Usmani SZ**, Plesner T, Avet-Loiseau H, Nijhof I, Mutis T, Schecter JM, Chiu C, Bahlis NJ. Deep Immune Profiling of Patients Treated with Lenalidomide and Dexamethasone with or Without Daratumumab. *Leukemia*. 2021 Feb;35(2):573-584. PMID: 32457357
- 144 . **Usmani SZ**, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma: Final Results from the Phase 2 GEN501 and SIRIUS Trials. *Lancet Haematol*. 2020 Jun;7(6): e447 -e455. doi: 10.1016/S2352-3026(20)30081-8. PMID: 32470437
- 145 . Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, **Usmani SZ**, McCarthy PL. Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. *Biol Blood Marrow Transplant*. 2020 Jun 23: S1083-8791(20)30366-9. doi: 10.1016/j.bbmt.2020.06.011. PMID: 32589921
- 146 . Yan X, Xu XS, Weisel KC, Mateos MV, Sonneveld P, Dimopoulos MA, **Usmani SZ**, Bahlis NJ, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma. *Clin Transl Sci*. 2020 Nov;13(6):1345-1354. PMID: 32583948
- 147 . Moore DC, Arnall JR, Thompson DL, Martin AL, Robinson J, Ndiaye A, Paul B, Atrash S,



- Bhutani M, Voorhees PM, **Usmani SZ**. Evaluation of Montelukast for the Prevention of Infusion-related Reactions with Daratumumab. *Clin Lymphoma Myeloma Leuk*. 2020 Jun 7: S2152 - 2650(20)30281-0. doi: 10.1016/j.clml.2020.05.024. PMID: 32660902
- 148 . Atrash S, Bhutani M, Paul B, Voorhees PM, **Usmani SZ**. Management of newly diagnosed transplant ineligible multiple myeloma. *Leuk Lymphoma*. 2020 Jul 4:1 -12. doi: 10.1080/10428194.2020.1786558. PMID: 32623918
- 149 . Paul B, Atrash S, Bhutani M, Voorhees P, Hamadeh I, **Usmani SZ**. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. *Expert Rev Hematol*. 2020 Aug;13(8):795-802. PMID: 32659139
- 150 . Paul B, Hamadeh I, Atrash S, Bhutani M, Voorhees P, **Usmani SZ**. Daratumumab Subcutaneous Formulation for the Treatment of Multiple Myeloma *Expert Opin Biol Ther*. 2020 Nov;20(11):1253-1259. PMID: 32750265
- 151 . Dhakal B, Hari PN, **Usmani SZ**, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. *Bone Marrow Transplant*. 2021 Jan;56(1):9-19. PMID: 32770147
- 152 . Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahiten-Kumeli A, **Usmani SZ**. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): primary analysis results from a randomized, multicenter, open-label, phase 3 study. *Lancet* 2020; 396(10245): 186-197. PMID: 32682484
- 153 . Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, **Usmani SZ**, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia*. 2021 Jan;35(1):18-30. PMID: 32778736
- 154 . Durie BGM, Kumar SK, **Usmani SZ**, Nonyane BAS, Ammann EM, Lam A, Kobos R, Maiese EM, Facon T. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma. *Am J Hematol*. 2020 Dec;95(12):1486-1494. PMID: 32804408
- 155 . **Usmani SZ**, Mateos MV, Hungria V, Iida S, Bahlis NJ, Nahi H, Magen H, Cavo M, Hulin C, White D, De Stefano V, Fastenau J, Slavcev M, Heuck C, Qin X, Pei H, Masterson T, Lantz K, Gries KS. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. *J Cancer Res Clin Oncol*. 2021 Feb;147(2):619-631. PMID: 32852632
- 156 . Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, **Usmani SZ**, Varnado W, Vij R, Costa L. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH. *Am J Hematol* . 2021 Jan;96(1):E5-E8. PMID: 32974944
- 157 . Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, **Usmani SZ**, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2020 Nov 1;6(11):1759-1765. PMID: 32970151
- 158 . Atrash S, Ali SA, **Usmani SZ**. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2020 Sep 18: S2152-2650(20)30518-8. doi: 10.1016/j.clml.2020.08.027. PMID: 33046423
- 159 . Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Gheraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, **Usmani S**, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working

Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer J.* 2020 Oct 16;10(10):102.doi: 10.1038/s41408-020-00366-3. PMID: 33067414.

162. Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampur DA. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. *J Clin Pharmacol.* 2021 May;61(5):614-627. PMID: 33145788
163. Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, **Usmani SZ**, San-Miguel J. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a cytogenetic subgroup analysis of POLLUX. *Blood Cancer J.* 2020 Nov 3;10(11):111. doi: 10.1038/s41408-020-00375-2. PMID: 33149130
164. Fonseca R, **Usmani SZ**, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer.* 2020 Nov 10;20(1):1087. doi: 10.1186/s12885-020-07503-y. PMID: 33172403
165. Gran C, Luong V, Bruchfeld JB, Liwing J, Afram G, Lund J, **Usmani S**, Alici E, Nahi H. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. *Am J Hematol.* 2020 Dec 2. doi: 10.1002/ajh.26062. PMID: 33264449
166. Costa LJ, Usmani SZ. Defining and Managing High-Risk Multiple Myeloma: Current Concepts. *J Natl Comprehensive Canc Network.* 2020 Dec 2;18(12):1730-1737. doi: 10.6004/jnccn.2020.7673. Print 2020 Dec. PMID: 33285523
167. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Findings from the Phase III MAIA Trial. *J Clin Oncol.* 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. PMID: 33326255
168. Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, **Usmani SZ**. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. *Clin Lymphoma Myeloma Leuk.* 2020 Nov 28: S2152-2650(20)30657-1. doi: 10.1016/j.clml.2020.11.015. PMID: 33339769
169. **Usmani SZ**, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomized, phase 2 trial. *Lancet Haematol.* 2021 Jan;8(1): e45-e54. doi: 10.1016/S2352-3026(20)30354-9. PMID: 33357482
170. Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, **Usmani SZ**, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis NJ. Evaluation of Sustained Minimal Residual Disease Negativity with Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. *J Clin Oncol.* 2021 Apr 1;39(10):1139-1149. PMID: 33513030
171. Murray DL, Puig N, Kristinsson S, **Usmani SZ**, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer J.* 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4. PMID: 33563895
172. Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, **Usmani SZ**, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampur DA, Gries KS, Qi M, Bahlis N, Ito S. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3

- COLUMBA study** Ann Hematol. 2021 Apr;100(4):1065-1077. PMID: 33599794
173. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, **Usmani SZ**. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4. PMID: 33602913
174. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, **Usmani SZ**, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7. PMID: 33662288
175. Sanikommu SR, Reese ES, He J, Lee C, Ai J, Butler CM, Jacobs R, Hu B, Atrash S, Trivedi J, Bhutani M, Voorhees P, **Usmani SZ**, Ghosh N, Fasan O, Druhan LT, Symanowski J, Copelan EA, Avalos BR. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation. J Clin Apher. 2021 Aug;36(4):553-562. PMID: 33710672
176. Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, **Usmani SZ**, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Expert review on soft tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 Aug;194(3):496-507. PMID: 33724461
177. Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, Rhee FV, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, **Usmani SZ**, Weisel KC, Zonder JA, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul;17(19):2499-2512. PMID: 33769076
178. Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, **Usmani SZ**. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. Clin Lymphoma Myeloma Leuk. 2021 Mar 4: S2152-2650(21)00088-4. doi: 10.1016/j.clml.2021.02.014. PMID: 33785299
179. Schmidt TM, Fonseca R, **Usmani SZ**. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. PMID: 33927196
180. Davies F, Rifkin R, Costello C, Morgan G, **Usmani S**, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021 Sep;100(9):2325-2337. PMID: 33970288
181. Caro J, Al Hadidi S, **Usmani S**, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar;41:291-309. PMID: 34010042
181. **Usmani SZ**, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. PMID: 34050260

182. van de Donk NWCJ, **Usmani SZ**, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. *Lancet Haematol*. 2021 Jun;8(6):e446-e461. doi: 10.1016/S2352-3026(21)00057-0. PMID: 34048683
183. Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, **Usmani SZ**, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. *Br J Haematol*. 2021 Aug;194(4):784-788. PMID: 34046887
184. Berdeja JG, Madduri D, **Usmani SZ**, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schechter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. PMID: 34175021.
185. Korde N, **Usmani SZ**. Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma. *Hematol Oncol Stem Cell Ther*. 2021 Jul 28;S1658-3876(21)00061-3. PMID: 34343494.
186. Sanikommu SR, Reese ES, He J, Lee C, Ai J, Butler CM, Jacobs R, Hu B, Atrash S, Trivedi J, Bhutani M, Voorhees P, **Usmani SZ**, Ghosh N, Fasan O, Druhan LJ, Symanowski J, Copelan EA, Avalos BR. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation. *J Clin Apher*. 2021 Aug;36(4):553-562. doi: 10.1002/jca.21892. Epub 2021 Mar 12. PMID: 33710672.
187. Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, **Usmani SZ**, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *Br J Haematol*. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16. PMID: 33724461.
188. Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, **Usmani SZ**, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. *Br J Haematol*. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28. PMID: 34046887.
189. **Usmani SZ**, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicenter, open-label, single-arm, phase 1 study. *Lancet*. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. PMID: 34388396.
190. Davies F, Rifkin R, Costello C, Morgan G, **Usmani S**, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. *Ann Hematol*. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10. PMID: 33970288; PMCID: PMC8357697.
191. Leleu X, Chari A, Richard S, Khurana M, Yusuf A, **Usmani SZ**. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. *Expert Rev Hematol*. 2021 Sep 21:1-10. doi: 10.1080/17474086.2021.1955343. Epub ahead of print. PMID: 34546844.



192. Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, **Usmani SZ**, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. *Transplant Cell Ther.* 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6. PMID: 34107340; PMCID: PMC8478786.
193. Martin T, **Usmani SZ**, Schechter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucl in CARTITUDE-1 versus idecabtagene vicleucl in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin.* 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23. Erratum in: *Curr Med Res Opin.* 2021 Oct 6;1-12. PMID: 34256668.
194. Jakubowiak A, **Usmani SZ**, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schechter JM, Chari A. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* 2021 Oct;21(10):701-710. doi: 10.1016/j.clml.2021.05.017. Epub 2021 Jun 9. PMID: 34274290.
195. Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E, Fox A, Atrash S, Paul B, Voorhees PM, **Usmani SZ**. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. *Cancer Med.* 2021 Oct;10(20):6933-6936. doi: 10.1002/cam4.4254. Epub 2021 Sep 8. PMID: 34494717; PMCID: PMC8525140.
196. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian- Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, **Usmani SZ**, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. *Bone Marrow Transplant.* 2021 Oct 4. doi: 10.1038/s41409-021-01455-y. Epub ahead of print. PMID: 34608275.
197. Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, **Usmani SZ**, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients with Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* 2021 Oct 30: S2152-2650(21)02416-2 doi: 10.1016/j.clml.2021.10.013. Epub ahead of print. PMID: 34840088.
198. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, **Usmani SZ**. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomized, open-label, phase 3 trial. *Lancet Oncol.* 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13. PMID: 34655533.
199. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, **Usmani S**, Shah N, Qazilbash M, D'Souza A. Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. *Transplant Cell Ther.* 2021 Nov 12: S2666-6367(21)01358-0. doi: 10.1016/j.jtct.2021.10.022. Epub ahead of print. PMID: 34781066.
200. Bal S, Malek E, Kansagra A, **Usmani SZ**, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJ. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. *Bone Marrow Transplant.* 2022 Jan;57(1):31-37. PMID: 34802043.
201. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, **Usmani SZ**, Hanbali A,

- Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. *Bone Marrow Transplant* . 2022 Feb;57(2):295-298. PMID: 34802047.
202. Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schechter JM, Banerjee A, Berdeja JG, Nesheiwat T, Garrett A, Qi K, Valluri S, **Usmani SZ**, Yong K. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. *Clin Drug Investig*. 2022 Jan;42(1):29-41. PMID: 34822128.
203. Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, **Usmani SZ**, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients with Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2021 Oct 30: S2152-2650(21)02416-2. doi: 10.1016/j.clml.2021.10.013. PMID: 34840088
204. Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, **Usmani S**, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzsch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer J*. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0. PubMed PMID: 34857730; PubMed Central PMCID: PMC8640034.
205. **Usmani SZ**, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomized, multicenter, open-label, phase 3 study. *Lancet Oncol*. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. PubMed PMID: 34871550.
206. Facon T, Cook G, **Usmani SZ**, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis NJ, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rempelbergh R, Uhlar CM, Kobos R, Zweegman S. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. *Leukemia*. 2022 Apr;36(4):1066-1077. PMID: 34974527
208. Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: a systematic literature review. *Blood Cancer J*. 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675
209. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, **Usmani S**, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther*. 2022 Mar 17: S2666-6367(22)01166-6. doi: 10.1016/j.jtct.2022.03.019. Online ahead of print. PMID: 35306217
210. **Usmani SZ**, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. *Haematologica* . 2022 Oct 1;107(10):2408-2417. PMID: 35354247
211. Paul B, Rodriguez C, **Usmani SZ**. BCMA-Targeted Biologic Therapies: The Next Standard of Care in

- Multiple Myeloma Therapy.** *Drugs.* 2022 Apr;82(6):613-631. PMID: 35412114
212. Malik MA, Sweeney NW, Jafri M, Derkach A, Chmielewski C, Adintori PA, Mailankody S, Korde N, Tan CR, Hassoun H, Hultcrantz M, Hillengass J, McCann SE, Iyengar N, **Usmani S**, Giralt SA, Landgren O, van den Brink MRM, Ahlstrom JM, Lesokhin AM, D'Souza A, Chimonas S, Shah UA. Nutrition perceptions, needs and practices among patients with plasma cell disorders. *Blood Cancer J.* 2022 Apr 20;12(4):70. doi: 10.1038/s41408-022-00666-w. PMID: 35443718
  213. Goel U, **Usmani S**, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. *Am J Hematol.* 2022 May;97 Suppl 1: S3-S25. doi: 10.1002/ajh.26512. Epub 2022 Mar 10. PMID: 35234302
  214. Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, **Usmani SZ**, McCarthy PL. Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. *Transplant Cell Ther.* 2022 May 20: S2666-6367(22)01312-4. doi: 10.1016/j.jtct.2022.05.019. Online ahead of print. PMID: 35605882
  215. Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, **Usmani SZ**. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. *Br J Haematol.* 2022 Sep;198(6):988-993. PMID: 35608261
  216. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, **Usmani S**, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther.* 2022 Jun;28(6):284-293. doi: 10.1016/j.jtct.2022.03.019. Epub 2022 Mar 17. PMID: 35306217
  217. Davies FE, Pawlyn C, **Usmani SZ**, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discov.* 2022 Jun 2: OF1-OF12. doi: 10.1158/2643-3230.BCD-21-0205. Online ahead of print. PMID: 35653112
  218. Martin T, **Usmani SZ**, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schechter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. *J Clin Oncol.* 2022 Jun 4: JCO2200842. doi: 10.1200/JCO.22.00842. Online ahead of print. PMID: 35658469
  219. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlir C, Stephenson T, Van Rempelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, **Usmani SZ**. Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2022 Aug 11;387(6):495-505. PMID: 35661166
  220. Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, **Usmani SZ**, Young JW, Zelenetz AD, Noy A, Vardhana SA. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. *Cancer Cell.* 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16. PMID: 35598602
  221. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlappalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, **Usmani SZ**, D'Souza A, Orlowski RZ,

- Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. *Am J Hematol*. 2022 Jul;97(7): E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2. PMID: 35472167
222. Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, **Usmani SZ**, Jagannath S, Callander NS, Berdeja JG, Kang Y, Vij R, Godby KN, Malek E, Neppalli A, Liedtke M, Fiala M, Tian H, Valluri S, Marino J, Jackson CC, Banerjee A, Kansagra A, Schechter JM, Kumar S, Hari P. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2022 May;22(5):326-335. doi: 10.1016/j.clml.2021.10.013. PMID: 34840088
223. Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomaso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, **Usmani SZ**, Rivière I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. *N Engl J Med*. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900. PMID: 36170501
224. Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan C, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, **Usmani SZ**, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MR, Lesokhin AM. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets. *Clin Cancer Res*. 2022 Sep 28;CCR-22-0723. doi: 10.1158/1078-0432.CCR-22-0723. PMID: 36170461
225. Weisel K, Krishnan A, Schechter JM, Vogel M, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, **Usmani SZ**, Berdeja JG, Jagannath S, Martin T. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2022 Sep;22(9):690-701. doi: 10.1016/j.clml.2022.04.025. PMID: 35764490
226. Martin T, Krishnan A, Yong K, Weisel K, Mehra M, Nair S, Qi K, Londhe A, Diels J, Crivera C, Jackson CC, Olyslager Y, Vogel M, Schechter JM, Banerjee A, Valluri S, **Usmani SZ**, Berdeja JG, Jagannath S. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. *EJHaem*. 2021 Dec 10;3(1):97-108. doi: 10.1002/jha2.312. eCollection 2022 Feb. PMID: 35846215
227. Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, **Usmani SZ**, Yeh TM, Olyslager Y, Goldberg JD, Schechter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. *Lancet Haematol*. 2022 Oct 7:S2352-3026(22)00284-8. doi: 10.1016/S2352-3026(22)00284-8. PMID: 36215989
228. Martin T, **Usmani SZ**, Schechter JM, Rocchia T, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Pacaud L, Garrett A, Bartlett M, Haltner A, Van Sanden S, Diels J, Valluri S, Samjoo IA. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin*. 2022 Nov 15:1-9. doi: 10.1080/03007995.2022.2139052. PMID: 36271807
229. Nath K, Shekarkhand T, Salcedo M, Derkach A, Rueda S, Chansakul A, Hulcrantz M, Korde N, Shah UA, Tan C, Chung DJ, Lahoud OB, Hassoun H, Lesokhin AM, Landau HJ, Shah G, Scordo M, Giralt SA, **Usmani SZ**, Roshal M, Landgren O, Mailankody S. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy. *Leuk Lymphoma*. 2022 Oct 25:1-5. doi: 10.1080/10428194.2022.2131417. PMID: 36282633
230. Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y,



- Shah GL, Lesokhin AM, Giralt SA, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, **Usmani SZ**, Jagannath S, Shah UA, Mailankody S, Parekh S. Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy. *Blood*. 2022 Nov 3:blood.2022017848. doi: 10.1182/blood.2022017848. PMID: 36327160
231. Maclachlan KH, Bagratuni T, Kastritis E, Ziccheddu B, Lu SX, Yellapantula V, Famulare CA, Argyropoulos KV, Derkach A, Papaemmanuil E, Dogan A, Lesokhin AM, **Usmani SZ**, Landgren O, Palomba ML, Maura F, Dimopoulos MA. Waldenström Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations. *Blood Adv*. 2022 Nov 4:bloodadvances.2022008876. doi: 10.1182/bloodadvances.2022008876. PMID: 36332058
232. Cohen AD, Hari P, Htut M, Berdeja JG, **Usmani SZ**, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. *Clin Lymphoma Myeloma Leuk*. 2022 Oct 11:S2152-2650(22)01692-5. doi: 10.1016/j.clml.2022.10.001. PMID: 36357295
233. Sklaventis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, **Usmani SZ**, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. *Cancer Cell*. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. PMID: 36379208
234. Foureau DM, Paul BA, Guo F, Lipford EH, Fesenkova K, Tjaden E, Drummond K, Bhutani M, Atrash S, Ndiaye A, Varga C, Voorhees PM, **Usmani SZ**. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2022 Oct 22:S2152-2650(22)01716-5. doi: 10.1016/j.clml.2022.10.008. PMID: 36443182
235. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Jr LDA, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, **Usmani SZ**, Richardson PG, Voorhees PM. Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. *Transplant Cell Ther*. 2022 Dec 6:S2666-6367(22)01802-4. doi: 10.1016/j.jtct.2022.11.029. PMID: 36494017
236. Pianko MJ, Tiutan T, Derkach A, Flynn J, Salvatore SP, Jaffer-Sathick I, Rossi AC, Lahoud O, Hultcrantz M, Shah UA, Maclachlan K, Chung DJ, Shah GL, Landau HJ, Korde N, Mailankody S, Lesokhin AM, Tan C, Scordo M, Jaimes EA, Giralt SA, **Usmani S**, Hassoun H. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. *Am J Hematol*. 2023 Jan 1. doi: 10.1002/ajh.26801. PMID: 36588413
237. Nahi H, **Usmani SZ**, Mateos MV, van de Donk NWCJ, Oriol A, Plesner T, Bandyopadhyay N, Hellems P, Tromp B, Nnane I, Zemlickis D, Chari A, Moreau P. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. *Leuk Lymphoma*. 2023 Jan 2:1-5. doi: 10.1080/10428194.2022.2148221. PMID: 36593729
238. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, **Usmani SZ**, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. *J Clin Oncol*. 2023 Jan 4;JCO2200940. doi: 10.1200/JCO.22.00940. PMID: 36599114
239. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, **Usmani SZ**, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective observational study. *Haematologica*. 2023 Jan 5. doi:

2. Reviews and Editorials:

1. **Usmani SZ**. Second Primary Malignancies and Myeloma Therapy: Fad or Fact? *Oncotarget*. 2012 Sep;3(9):915-6. PMID:22989934
2. **Usmani SZ**. Melphalan Continues to Rock the Myeloma World. *Biol Bone Marrow Transplant* 2013;121(10):1819-23. PMID:23462187
3. Johnson SK, Barlogie B, **Usmani SZ**. What can we attribute secondary malignancy to; drugs or the innate system? *Int. J. Hematol. Oncol.* 2013;2(2):87–90.
4. Atrash S and **Usmani SZ**. Clinical and Biologic Predictors of High Risk Multiple Myeloma. *TreatmentStrategies-Hematology* 2013;3(1):49-52.
5. **Usmani SZ**, Hoering A. Heterogeneity of Outcome with Single-agent Carfilzomib - All Relapsed/Refractory Myelomas Are Not Created Equal. *Leukemia* 2013;27(12):2269-71. PMID:24326595
6. **Usmani SZ**. How Long Can We Let the Myeloma Smolder? *Expert Rev Hematol.* 2014 Feb;7(1):17-9. PMID: 24382208
7. **Usmani SZ**. Role of Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma. *HemOnc Today* 2014
8. **Usmani SZ**. Optimal Induction Treatment for Transplant Ineligible Newly Diagnosed Multiple Myeloma. *HemOnc Today* 2014
9. **Usmani SZ**. Best of ASCO 2015 Highlights in Plasma Cell Disorders. *Clinical Oncology News* 2015
10. **Usmani SZ**. Daratumumab for Relapsed/Refractory Multiple Myeloma. *HemOnc Today* 2015
11. Fasan O, **Usmani SZ**. Bone Health in Multiple Myeloma. *Clinical Oncology News* 2015
12. **Usmani SZ**. Keep Calm, It's Just The Proteasome. *ASH News Daily 2015 Annual Meeting.*
13. **Usmani SZ**. Where Have All the Neutrophils Gone? *ASH News Daily 2015 Annual Meeting.*
14. **Usmani SZ**. “Hey, Don't Burst My Bubble”. *ASH News Daily 2015 Annual Meeting.*
15. **Usmani SZ**. Factor VIII Source Matters! (Or Does It?). *ASH News Daily 2015 Annual Meeting.*
16. **Usmani SZ**. The Vampire Diaries: The Art and Science of Blood Transfusions. *ASH News Daily 2015Annual Meeting.*
17. **Usmani SZ**. So, You Know How to Treat, But Do You Know How to Tweet? *ASH News Daily 2015 Annual Meeting.*
18. **Usmani SZ**. A Good Year for Multiple Myeloma Patients and Research. *Clinical Oncology News* 2016
19. **Usmani SZ**. What is the recommended method of risk stratification for myeloma? *ASCO Daily News* 2016.
20. **Usmani SZ**. Maintenance lenalidomide after transplant; how much is enough? *Cancer* 2016. doi: 10.1002/cncr.30363. PMID: 27680532
21. **Paul B and Usmani SZ**. Selinexor/Dexamethasone in Refractory Multiple Myeloma: The STORM Has Arrived, but Does It Represent Climate Change? *ASCO Post*, November 25, 2019.
22. **Bhutani M and Usmani SZ**. Quadruplets Come of Age for Newly Diagnosed Multiple Myeloma. *Lancet*2019 Dec 10[Online ahead of print]. PMID: 31836198 DOI: 10.1016/S0140-6736(19)33063-6.
23. **Atrash S and Usmani SZ**. Mye-llennial Dilemma: What Are the Optimal Endpoints for Multiple Myeloma Clinical Trials? <https://pub.hematology.org/Thehematologist/Op-Ed/12884901897.aspx>

3. Books:

1. Editor, Nova Publishers Book entitled **Heat Shock Proteins: Classification, Functions andApplications**; 2013; ISBN: 978-1-62417-571-8
2. Editor, Springer Book titled **Personalized Therapy for Multiple Myeloma**: 2017. ISBN 978-3-319-61872.2

4. Chapters:

1. Boota M, Singh Z, Bornhorst J, **Usmani SZ**. Book chapter entitled “Novel Prognostic Modalities in Multiple Myeloma” Intech Publishers Book entitled “**Multiple Myeloma**”; 2013; ISBN 980-953-307-822-4.

2. **Hussain MJ and Usmani SZ**. Book chapter titled “Hematopoietic Cell Transplantation in Patients With Multiple Myeloma”. Elsevier Book Titled “Hematopoietic Cell Transplantation for Malignant Conditions”. ISBN 978-0-323-56802-9
3. **Sydney Lu, Rustad E, Usmani SZ, Landgren O**. Multiple Myeloma, Hematology: Basic Principles and Practice, 8th edition (In press).
5. Non-peer-reviewed Research Publications: N/A
6. Case Reports (*optional, or list 10 best*): N/A
7. Guidelines (*if not listed above*): N/A
8. In review (*manuscripts submitted or in preparation – list separately*): N/A
9. Abstracts (*optional, list 10-20 best or most recent only*): N/A
10. Other (*media, podcasts, etc.*): N/A